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1.1. NATURAL KILLER CELLS 
Natural Killer (NK) cells were first described in 1975 (1–3) and were named based on their description 
as cytolytic effector immune cells, which can rapidly induce the death of tumour and virus-infected 
cells in the absence of a prior specific immunization. NK cells are large granular cells classified as 
lymphocytes based on their morphology, surface markers, and origin from a Common Lymphoid 
Progenitor (CLP) (4–6). In particular, NK cells belong to the expanding family of Innate Lymphoid Cells 
(ILCs): based on their cytokine and transcription factor expression, NK cells are classified as ILC1, a 
group composed of T-bet-expressing cells, such as liver, thymic, and intraepithelial ILC1, able to release 
type 1 cytokines (7,8). Unlike T and B lymphocytes, NK cells components of the innate immune system 
because of the lack of antigen and clonal specificity and of long-lived memory. However, recent 
findings demonstrated that NK cells display some of the features typical of adaptive immunity, thus 
collocating them at the boundary between adaptive and innate immunity (9,10). NK cells can be found 
not only in the blood stream but also in lymphoid organs and in non-lymphoid peripheral tissues (5,11–
14). The few reports of complete NK cell deficiencies in humans, resulting in uncontrollable fatal 
infections during childhood (15,16), support the notion of NK cell importance in host defence, 
especially in the early control against viral infection and in tumour immunosurveillance. Moreover, the 
presence of NK cells in other mammals and of NK cell orthologues in different vertebrates (i.e. fish, 
amphibians, and chicken) (17), as well as the particular role that NK cells exert in the uterus during 
pregnancy (18–20), argue for their importance and for their positive selection during evolution. 
1.1.1. NK cell populations  
NK cells constitute one of the three major lymphocyte subsets (i.e. B cells, T cells, and NK cells), since 
they represent approximately 10–15% of lymphocytes in peripheral blood. However, NK cells can also 
be found in lymphoid organs and non-lymphoid peripheral tissues (i.e. liver, lung, omentum, intestine, 
and placenta), where in the last years, an increasing number of unique and tissue-specific NK cell 
populations has been characterised (5,6,11–14).  
CD56bright and CD56dim NK cell subsets 
The first and better characterised NK cell subsets were those characterised by the CD56bright or CD56dim 
phenotype (4,6,21,22). CD56 is a glycoprotein belonging to Neural Cell Adhesion Molecule (NCAM) 
family, probably involved in mediating NK interactions with other cells, and was recently shown to be 
implicated in pathogen recognition (23). Early studies on NK cells described CD56 molecule as a marker 




allowing the identification of mature NK cells, based on its cell surface density which correlates with 
the expression of other surface molecules responsible for the different phenotype, tissue localisation, 
and functions characterising CD56brightCD94/NKG2A+CD16-KIR- and CD56dimCD94/NKG2A+/-CD16+KIR+ 
NK cell subsets (Fig. 1) (4,6,21,22). The different expression pattern of cell surface molecules involved 
in NK cell trafficking, suggests that CD56bright and CD56dim NK cells likely migrate to distinct sites in vivo: 
indeed, CD56bright NK cells represent only 10% of circulating NK cells, but they are enriched up to 90% 
in secondary lymphoid organs and in non-lymphoid tissues. Conversely, CD56dim NK cells largely 
predominate in peripheral blood and are poorly represented in other tissues (4,6,21,22). These 
differences result in the release of distinct cytokines, and in dissimilar cytotoxic and proliferating 
capabilities: in particular, up to recent years, the existence of a clear functional distinction between 
cytokine-releasing CD56bright and cytotoxic CD56dim NK cells was a general belief. However, recent 
studies showed that also CD56dim cells can release high amounts of cytokines but preferably upon 
contact with target cells, instead of in response to soluble factors as for CD56bright NK cells (24,25). 
Moreover, CD56dim and CD56bright NK cells display a different cytokine release kinetics, since interferon 
(IFN)- secretion by CD56dim NK cells occurs only at early times (2 to 4 h) upon cell stimulation, whereas 
IFN- release by CD56bright NK cells is more delayed (26). 
 
Figure 1. CD56bright and CD56dim NK cell subsets  
Mature NK cells can be divided in two main cell subsets based on CD56 cell surface expression levels. Here 
the main surface markers, released cytokines, and effector functions of CD56bright and CD56dim NK cells are 
summarised. Adapted from (27). 
Decidua-resident NK cells 
Decidua-resident NK (dNK) cells are one of the most studied tissue-resident NK cell subsets: they derive 
from a CD34+ progenitor in the uterus or from peripheral NK cells (pNK) acquiring the dNK cell 
phenotype (CD56brightCD16-KIR+) when exposed to Transforming Growth Factor (TGF)-, hypoxia, or 
demethylating agents. dNK cells represent up to 50-90% of lymphoid cells during the first trimester of 
pregnancy and are responsible for the production of cytokines, chemokines, and angiogenic factors 
(18–20). It is important to note that some activating NK cell receptors (NKp44, NKp46, DNAX Accessory 




Molecule-1 (DNAM-1), and NKG2D) can recognise ligands expressed on human trophoblast: such 
interaction results in the triggering of cytokine release, but not in the induction of cytotoxic activity 
(28). Collectively, all dNK cell-derived soluble factors mediate key physiological processes required for 
successful pregnancy, such as regulating placentation and vascular remodelling of spiral arteries, and 
creating an immunosuppressive microenvironment able to allow the presence of a semi-allogeneic 
foetus. Importantly, dNK cells contribute to immunosuppression both through TGF- release and 
through the interaction with decidual CD14+ monocytes, able to induce the differentiation of 
regulatory T lymphocytes (Treg) (29). Interestingly, it has been shown that dNK cell dysfunction can be 
associated to unsuccessful pregnancy (18–20).  
1.1.2. NK cell functions 
Immunoregulatory functions 
NK cells can regulate both innate and adaptive immune responses through the interaction with 
different immune cell types, including neutrophils, basophils, macrophages, Dendritic Cells (DCs), and 
T lymphocytes. Such immunoregulatory interactions, mediated by both cytokine secretion and cell-to-
cell contacts, contribute to NK cell antimicrobial and anti-tumour functions (6,21,22,30).  
In response to cytokines, CD56bright NK cells are primarily able to produce cytokines, such as IFN-, 
Tumour Necrosis Factor (TNF)-, TNF-, IL-10, IL-13, Granulocyte Macrophage-Colony Stimulating 
Factor (GM-CSF), and several chemokines. Since during infections NK cells are activated earlier than T 
cells, IFN- produced by NK cells is essential during the first phases of the immune response: IFN- is 
involved in macrophage activation, T cell polarization towards TH1 response, and enhancement of 
antigen presentation through the up-regulation of Human Leukocyte Antigen (HLA) class I and class II 
molecules. NK cells also release chemokines, such as CXCL12, CCL3, CCL4, and CCL5, that recruit 
immune cells in the site of inflammation, whereas GM-CSF induces haematopoiesis and DC maturation 
(6,21,30).  
One of the most studied NK cell interactions is the NK-DC bidirectional crosstalk that can occur in the 
periphery or in secondary lymphoid tissues, and results in DC-induced NK cell proliferation, NK cell-
dependent DC maturation, and NK cell-mediated killing of immature DCs (iDCs) (30–33). DCs, 
undergoing maturation following antigen uptake, release cytokines that induce NK cell proliferation, 
cytotoxicity, and IFN- release. Both iDCs and mature DCs (mDCs) express ligands recognised by 
activating NK cell receptors, such as NKp30 and DNAM-1, and able to induce both IFN- secretion and 
killing of iDCs which failed to up-regulate HLA-I expression. This editing process allows the survival only 
of mDCs able to efficiently induce TH1 response (30–33).  
As far as NK-neutrophil interaction is concerned, neutrophils can modulate NK cell survival, 
proliferation, cytotoxicity, and cytokine release; on the other hand, NK cells release IFN- and GM-CSF, 




promoting neutrophil survival and Reactive Oxygen Species (ROS) production during early 
inflammation; moreover, NK cells can turn down neutrophil response by inducing apoptosis through 
an NKp46- and Fas-dependent mechanism (34,35). NK cells also interact with eosinophils: following 
direct contact with these cells, NK cells release higher IFN- amounts, kill tumour cells more efficiently, 
and promote adaptive immune responses through the DC editing process. In turn, NK cells induce the 
acquisition of an Antigen Presenting Cells (APC)-like phenotype in eosinophils that up-regulate HLA-I 
and -II molecules; however, NK cells can also kill eosinophils, suggesting a role for NK cells in 
dampening eosinophil-mediated immune response (36). The immunoregulatory role of NK cells has 
been investigated also in the context of NK-macrophage crosstalk. M1-polarised macrophages release 
IL-12, which stimulates IFN- production by NK cells and, in turn, NK cell-derived IFN- induces IL-12 
release by macrophages. These effects are mediated both by cell-to-cell contact and by M1-derived IL-
18. IL-12-activated NK cells acquire the ability to kill M0 unpolarised and M2-polarised macrophages: 
these cells, similarly to Tumour Associated Macrophages (TAMs), are unable to release IL-12, thus they 
do not activate NK cell functions (37).  
NK cells can also interact with different non immune cell types: several studies analysed the interaction 
between Mesenchymal Stem Cells (MSCs) and NK cells. MSCs can inhibit NK cell proliferation through 
the release of soluble factors, whereas the impairment of NK cell-mediated cytotoxicity and cytokine 
release also requires cell-to-cell contact. It has been shown that both indoleamine 2,3-dioxygenase 
(IDO) and prostaglandin E2 (PGE2), expressed/produced by MSCs, are involved in the inhibition of NK 
cell proliferation, while PGE2 and soluble HLA-G play a role in the impairment of NK cell cytotoxicity. 
In addition, MSCs have been reported to inhibit the expression of NKp44, NKp30, and NKG2D activating 
receptors, thus affecting NK cell activation (38). 
Cytotoxic activity 
While CD56bright NK cells play an important immunoregulatory role, they are less effective mediators of 
cytotoxicity, as compared to CD56dim NK cells, which express higher levels of granzymes, perforin, 
CD16, and receptors involved in the induction of natural cytotoxicity. In the presence of target cells, 
NK cells can mediate two different types of cytotoxic activity: Antibody-Dependent Cell-mediated 
Cytotoxicity (ADCC) and natural cytotoxicity. ADCC is strictly dependent on CD16 receptor (FcRIII), 
which binds the Fc portion of IgG on opsonised targets (4,6,21,22,24,27). Differently, natural 
cytotoxicity is finely tuned by a series of activating and inhibitory receptors expressed on NK cells and 
able to interact with their respective ligands on target cells. Early studies on NK cell functions suggested 
the ability of these cells to recognise and kill autologous cells lacking the expression of HLA-I, a class of 
self-molecules normally expressed on all human cells but often down-regulated by tumour and virus-
infected cells in order to avoid T cell-mediated recognition. Following these observations, Kärre et al. 
proposed the “missing-self hypothesis”, according to which the absence of inhibitory signals 




transduced by receptors recognising HLA-I molecules results in the induction of target cell killing (39). 
Subsequent studies revealed a more complex regulation, since the induction of NK cell cytotoxicity not 
only requires the absence or the partial loss of inhibitory signals, but also the transduction of activating 
signals (overcoming the inhibitory ones), mediated by the interaction of activating receptors with their 
respective ligands on target cells (25).  
The main effector molecules involved in NK cell-mediated cytotoxicity are perforin and granzymes: 
perforin creates pores in the phospholipid bilayer of target cells, facilitating the entry of granzymes, a 
family of serine proteases located in cytolytic granules of cytotoxic T and NK cells. Granzyme B can 
mediate caspase cleavage and activation, resulting in the induction of cell death by apoptosis (40).  
1.1.3. NK cell receptors  
Activating and inhibitory receptors involved in the regulation of cytotoxic activity can be primarily 
divided in two classes based on their ligands: receptors recognising HLA-I molecules and receptors 
specific for non-HLA ligands.  
HLA-I specific receptors 
Killer Immunoglobulin-like Receptors (KIRs)  
The most important HLA-I-specific receptors are Killer Immunoglobulin-like Receptors (KIRs), a family 
of highly polymorphic receptors recognising HLA-A, -B, and -C molecules (25,39,41). KIRs are sets of 
paired inhibitory (iKIRs) and activating (aKIRs) receptors characterised by either two (KIR2D) or three 
Ig-like (KIR3D) extracellular domains and a cytoplasmic tail that defines their functional properties. In 
particular, iKIRs display a long cytoplasmic tail (KIR2DL and KIR3DL) containing an Immunoreceptor 
Tyrosine-based Inhibition Motif (ITIM) sequence, whose phosphorylation upon receptor engagement 
results in the recruitment of phosphatases able to dampen early activation signals derived by activating 
receptors. aKIRs share the same structure of iKIRs, but are characterised by a short cytoplasmic tail 
(KIR2DS and KIR3DS) that associates with DNAX-activation protein (DAP) 12, an adaptor protein 
bearing Immunoreceptor Tyrosine-based Activation Motif (ITAM) sequences, necessary for the 
transduction of activating signals (25,42,43). KIRs allow NK cells to sense target cells with absent or 
reduced expression of HLA-I, therefore complementing T cell surveillance directed towards HLA-I-
expressing cells: each KIR recognises epitopes shared within a group of HLA-I alleles; nevertheless, it 
has been observed that for many HLA-I alleles there is no corresponding KIR, while, on the other hand, 
some KIR ligands are still elusive, especially in the case of aKIR ligands (44–46). Curiously, KIRs do not 
necessarily recognise only HLA-I molecules: increasing evidence suggests that some aKIRs are also able 
to detect viral peptides, presented by HLA-I, and CpG oligodeoxynucleotides (ODNs): these 




observations suggest that KIRs can act as sensors for changes in peptidome and microbial products 
during viral infection (45,47,48). 
KIRs are clonally distributed within the NK cell population; indeed, NK cells can express one to eight 
different activating or inhibitory KIRs, depending on a stochastic process involving DNA silencing and 
DNA methylation of KIR genes (44,49,50). Since KIRs are clonally expressed on NK cells, and KIR and 
HLA genes are independently inherited, not all NK cells display an inhibitory receptor recognising self-
HLA-I molecules: this situation could potentially result in the presence of a subset of autoreactive NK 
cells. However, it has been observed that NK cells expressing inhibitory KIRs for self-HLA-I are more 
responsive than potentially autoreactive cells: this observation led to the concept of NK cell education 
or licensing (49,50). 
NKG2 receptor family 
NK cells are also able to assess the overall expression levels of HLA molecules through the interaction 
between receptors belonging to the NKG2 family and the non-classical HLA-I molecule HLA-E. HLA-E 
presents peptides deriving from the leader sequences of classical HLA-I molecules; therefore, its 
expression levels reflect those of all the other classical HLA-I molecules (51,52). NKG2 receptor family 
includes five molecules (i.e. NKG2A, NKG2B, NKG2C, NKG2E, and NKG2F) which can associate with 
CD94 to form heterodimeric C-type lectin receptors, and the NKG2D receptor, which does not 
associate with CD94 and does not recognise HLA-E. In the case of NKG2F, its interaction with HLA-E has 
not yet been demonstrated. Similar to KIRs, NKG2 receptor family includes both activating and 
inhibitory molecules: CD94/NKG2A and CD94/NKG2B are inhibitory receptors characterised by a long 
cytoplasmic tail containing an ITIM sequence responsible for the transduction of inhibitory signals. The 
activating counterparts display a short cytoplasmic portion and are coupled with DAP12 transducing 
molecule (52). The expansion of NKG2C+ NK cells has been demonstrated in the blood of 
Cytomegalovirus (CMV)-infected patients: NKG2C receptor appears to play a key role in this process 
through the recognition of HLA-E molecules loaded with viral peptides (53). 
Immunoglobulin-like Transcript 2 (ILT2) receptor 
ILT2, also known as Leukocyte Ig-like Receptor (LIR)-1, is a member of a receptor family mainly 
expressed on myeloid cells: similar to CD94/NKG2A, ILT2 senses the overall HLA-I expression and 
transduces inhibitory signals upon recognition of the non classical HLA-I molecule HLA-G (51,54). 
NK cell receptors specific for non HLA-I ligands  
NK cells also express an array of receptors that do not recognise HLA-I molecules: this group includes 
activating receptors, such as CD16, NCRs (Natural Cytotoxicity Receptors), DNAM-1, NKG2D, NKp80, 
NTB-A (NK-T-B-antigen), and 2B4 (42), as well as inhibitory receptors, such as IRp60 (Inhibitory 
Receptor protein 60) (55).  





CD16, also known as FcRIII, is the low affinity receptor for the Fc portion of IgG: upon recognition of 
antigen-antibody complexes, signal transduction through the CD3 adaptor protein leads to the 
induction of ADCC. Since this process requires the presence of antibodies, it is induced only following 
activation of adaptive immunity and the subsequent production of IgG (6). 
Natural Cytotoxicity Receptors (NCRs)  
 
Figure 2. Schematic representation of NCR structure  
For each receptor, the structure of the canonical isoform is represented together with the associated 
adaptor molecules. Ig domains are coloured in blue, activating ITAM in green, and inhibitory ITIM in red. 
The amino acids responsible for the association with adaptor molecules are indicated in the black boxes. 
Adapted from (56). 
The NCR family includes three different receptors displaying similar functions (42,57), namely NKp46 
(NCR1; CD335) (58,59), NKp44 (NCR2; CD336) (60,61), and NKp30 (NCR3; CD337) (62). NKp46 and 
NKp30 are expressed on both resting and activated NK cells, while NKp44 is expressed only upon IL-2-
mediated NK cell activation. Ncr1 gene is encoded within chromosome 19 (and its mouse orthologue 
on chromosome 7), while the genes coding for NKp44 and NKp30 are located on chromosome 6 
(59,61,62). NCRs are type I transmembrane proteins belonging to the Ig superfamily, displaying one 
(NKp30 and NKp44) or two (NKp46) Ig-like domains that are responsible for ligand binding. NCRs 
associate with different ITAM-containing adaptor molecules able to transduce activating signals upon 
receptor engagement (Fig. 2) and can also form homodimeric structures with a disulfide bridge (63–
66). A peculiar functional crosstalk among NCRs has been reported, since the engagement of one NCR 
appears to initiate both its own signal transduction cascade and the ones downstream of other NCRs 




(67). Moreover, it was observed that NK cell activation is more efficient when different NCRs are 
activated, since target cells can express multiple NCR ligands.  
NKp46 
NKp46 is the only NCR that has an orthologue in other non-primate species, such as rat and mouse: 
this specific evolutionary conservation suggests that NKp46 could be the primary NCR involved in 
pathogen and tumour recognition (68,69). NKp46 displays two N-terminal C2-type Ig-like domains and 
associates with CD3 and the -chain of FcRI through a positively charged Arg residue in the 
transmembrane domain (58,59). It has been shown that NKp46 can dimerize and that disruption of the 
dimer prevents ligand binding and receptor activating function (64). 
NKp46 is expressed by all mature NK cells, in a small subset of T cells, and in some ILC populations, 
such as ILC3; nevertheless, it has been shown to be a more selective marker for NK cells and to better 
characterize them through species, as compared to CD56 (70). NKp46 expression can be down-
modulated by exposure to L-kynurenine in the tumour microenvironment (TME) or by cortisol and 
methylprednisolone, while it is up-regulated in the presence of IFN-, IL-2, and prolactin (71–73).  
NKp30 
NKp30 is characterised by an extracellular region containing one Ig domain and a proximal region rich 
in hydrophobic amino acids that could be involved in the interaction with its respective ligands. NKp30 
ligand binding and signalling function are highly dependent on the integrity of the membrane-proximal 
stalk region (74). Six NKp30 isoforms have been identified: in particular, NKp30 a, b, and c isoforms 
display an extracellular V-type Ig domain, while d, e, and f isoforms encode for receptors characterised 
by a C2-type Ig domain lacking 25 amino acids (75). The transmembrane portion contains a positively 
charged residue (Arg) involved in the interaction with the signalling adaptor molecule CD3 (62). 
NKp30 splice variants also differ in the cytoplasmic region, since splice variations within exon 4 
generate three different portions, resulting in either immunostimulatory or immunosuppressive 
functions. The d, e, and f isoforms have not been studied to date, in contrast to a, b, and c isoforms, 
whose differential expression and function have been examined in various settings (75–78). 
NKp30 is expressed on all resting and activated mature NK cells, but can also be found on the surface 
of cord blood T cells upon IL-15 exposure (79), on endometrial epithelial cells after progesterone 
stimulation (80), and on V1+ T cells upon TCR engagement (81). NKp30, as well as NKp46, is down-
modulated by cortisol and methylprednisolone, while it is increased in the presence of IFN-, IL-2, and 
prolactin (71,72); by contrast, TGF- has been shown to selectively down-regulate NKp30, but not 
NKp46 expression (82).  





NKp44 (60,61) is characterised by an extracellular Ig-like domain at the N-terminal that adopts a V-
shaped conformation with a large positively charged groove on one face of the domain: this region 
could provide a binding site for yet unknown anionic ligand(s) on tumour cells (57,65). NKp44 also 
displays a 64 amino acid link region (stalk domain) containing 13 O- and 1 N-glycosylation predicted 
sites, a transmembrane domain, and a short intracellular tail. Ncr2 gene comprises five exons, but two 
splice variants containing an additional exon have been reported (Fig. 3). NKp44RG1 (NKp44-3) variant 
has an additional exon that adds 35 amino acids to the protein but modifies the reading frame, 
resulting in a shorter cytoplasmic tail. The NKp44RG2 (NKp44-2) variant displays not only this 
additional exon, but also a 36 bp extension at the 5’ of exon 4 encoding 12 additional amino acids (83). 
To date, no NKp44 gene has been mapped in the syntenic region of mouse chromosome 17, but an 
orthologue was found in various primate species (83,84), suggesting that NKp44 could be the last NCR 
gene appeared in phylogenesis. Only the NKp44-1 isoform contains in the cytoplasmic tail an ITIM 
sequence (EILYHTVA), which is absent in the other two isoforms due to alternative splicing. NKp44-1 
isoform is more expressed by dNK than by pNK cells, and an increased expression of NKp44-2 and -3 
isoforms in dNK cells has been shown to correlate with an increased risk of miscarriage (76,77). These 
observations may indicate that the ITIM sequence in NKp44-1 isoform could be involved in maintaining 
dNK cells in a status of tolerisation towards the semi-allogeneic foetus. NKp44 is coupled through a Lys 
residues in the transmembrane region to a dimer of the ITAM-containing adaptor molecule DAP12 for 
downstream signal transduction (60,61); the association between NKp44 and DAP12 is also essential 
for NKp44 surface expression.  
 
Figure 3. Schematic representation of NKp44 gene and its splice variants  
For each splice variant, exon and intron lengths are specified; different colours represent various encoded 
domains as indicated. Ncr2 exon lengths, but not intron lengths, are represented in scale with the real 
ones. Adapted from http://atlasgeneticsoncology.org 
NKp44 is usually expressed by NK cells only upon activation with IL-2, IL-15, or IL-1, but is 
constitutively expressed by dNK cells. NKp44 is also expressed by ILC3 NCR+ cells, in which NKp44 
engagement induces TNF production (85), and by pDCs, whose IFN- production is paradoxically 
inhibited upon NKp44-mediated stimulation (86). IL-2-induced up-regulation of NKp44 receptor on NK 
cells can be inhibited by prostaglandin E2 (PGE2), produced, for example, by Tumour-Associated 
Fibroblasts (TAFs) (87); a similar effect is also exerted by prednisolone (71). 





NKG2D (CD314) is an activating C-type lectin receptor, constitutively expressed by all NK cells and by T 
cells and belonging to the NKG2 receptor family. It associates with DAP10 adaptor protein, containing 
a YINM sequence and involved in the transduction of activating signals upon interaction with its ligands 
(88–90). Infected and transformed cells usually activate stress responses, such as the DNA damage 
response, inducing the overexpression of NKG2D ligands, represented by Major Histocompatibilty 
Complex (MHC) class I Chain-related protein A and B (MICA/B) and UL16-Binding Proteins (ULBPs)-1/6 
(88–90). MICA/B molecules are expressed by the gastrointestinal epithelium in normal conditions, and 
can be up-regulated in different cancers, including epithelial, lung, breast, kidney, ovary, prostate, 
colon tumours, and melanoma. They are transmembrane molecules containing the 1, 2, and 3 
HLA-I-like domains, but neither associate with 2-microglobulin nor bind any peptide. ULBP-1, -2, and 
-3 are GPI-anchored surface molecules, whereas ULBP-4 contains a transmembrane domain and a 
cytoplasmic portion: ULBPs are expressed by both normal tissues and tumours and are characterised 
by 1 and 2 chains that resemble those of HLA-I molecules (88–92).  
DNAM-1 
DNAM-1 (CD226) is a transmembrane protein that can transduce activating signals through the 
phosphorylation of tyrosines in its cytoplasmic tail, resulting in the enhancement of cytotoxicity and 
cytokine production by NK cells. DNAM-1 is characterised by two extracellular Ig-like domains and a 
cytoplasmic portion containing three tyrosine residues. In addition to NK cells, also T cells, monocytes, 
and a small subset of B lymphocytes express this receptor (93,94). DNAM-1 binds two members of the 
nectin family: CD112 (Nectin-2) and CD155 (Poliovirus Receptor, PVR), two closely related molecules 
that are highly expressed on several tumour cell types (95). Nectins are widely expressed also on 
normal cells, including neurons, epithelial, endothelial cells, and fibroblasts; this implies that normal 
cells are protected against NK cell cytotoxicity by the expression of self HLA-I molecules (95,96). Based 
on DNAM-1 ligand expression levels, a remarkably heterogeneous tumour susceptibility to NK cell-
mediated lysis among different patients was observed in different types of tumours, such as 
neuroblastoma and leukaemia (96). Interestingly, DNAM-1 ligands are also able to interact with TIGIT 
(T cell Immunoreceptor with Ig and ITIM domains) and CD96 inhibitory receptors: both receptors can 
be expressed on NK cells and bind PVR with a higher affinity than DNAM-1. Thus, TIGIT and CD96 can 
compete with DNAM-1 for ligand recognition, and can counterbalance DNAM-1-mediated NK cell 
activation (94,97,98).  
IRp60 
IRp60 (also known as CD300a or CMRF35-H9) is expressed by all NK cells and by other cell types, 
including T lymphocyte subsets, monocytes, and granulocytes. In NK cells, it has been shown to inhibit 
the cytotoxic activity induced by different activating NK receptors (55,99). IRp60 is a 60 kDa surface 




molecule belonging to the Ig-superfamily, displaying one extracellular Ig-V domain and a cytoplasmic 
tail containing three classical and one non-classical ITIM motifs that are tyrosine phosphorylated upon 
receptor engagement. IRp60 is highly related to five CMRF35 proteins encoded in the same gene 
cluster on chromosome 17, where IRp60 gene is located; in particular, CMRF35-A (CD300c) shares high 
similarity with IRp60, but does not contain any ITIM in its intracellular portion and may thus display an 
activating function (55,100).  
Recently, two ligands for IRp60 have been identified: this receptor is able to bind 
phosphatidylethanolamine and phophatidylserine and to subsequently transduce an inhibitory signal 
that suppresses NK cell-mediated cytotoxicity (101,102).  
1.1.4. NCR ligands 
Until now, only some NCR ligands have been identified: NCRs are able to recognise a wide spectrum of 
ligands of different origin, ranging from viral, parasite, and bacterial ligands to cellular ones (Table 1), 
thus playing a key role in the recognition and killing of infected and tumour cells. The very different 
nature of these molecules, together with the possible low affinity of ligand-receptor interactions, may 
be one reason hindering the identification of novel ligands. Other factors could be related to the 
chemical nature of the ligands (they might be not only proteins, but also sugars, lipids, or complex 
structures), or to the possibility that the formation of receptor complexes is necessary for a more stable 
receptor-ligand interaction (56,103–105). 
NKp46 ligands 
NKp46 recognises different viral ligands, such as hemagglutinin (HA) of influenza and Sendai virus 
(106,107), and hemagglutinin-neuraminidase (HN) of Newcastle Disease virus and Orthopox virus 
family (108,109). Among other microbial ligands, unknown ligands on Plasmodium falciparum (110) 
and Fusobacterium nucleatum (111), as well as the glycan-binding lectins Epa1, Epa6, and Epa7 of 
Candida glabrata (112), were identified.  
Vimentin, an intracellular filamentous protein that is part of the cytoskeleton, was the first identified 
NKp46 cellular ligand: in particular, a peculiar form of vimentin can be expressed on the cell surface of 
Mycobacterium tuberculosis-infected monocytes, where it is recognised by NK cells and stimulates 
their cytotoxic activity (113). More recently, NKp46 has been shown to recognise unknown ligands 
expressed on healthy tissues, such as salivary glands, hepatic stellate cells, and pancreatic -cells; 
importantly, NK cell- mediated recognition of pancreatic -cells has been correlated to the 
development of type I diabetes (114–116). NKp46 ligands are also expressed on tumour cells (42,56), 
but the identity of these molecules is still unknown.  
The most recently identified NKp46 ligand is the Complement Factor P (CFP or properdin), a plasma 
glycoprotein produced by neutrophils, monocytes, and T cells, able to positively regulate the 




alternative complement pathway. Narni-Mancinelli et al. reported that CFP-NKp46 interaction does 
not affect neither NK cell degranulation nor IFN- secretion, while it has been suggested that, through 
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C. glabrata Fungal wall (112) 
Vimentin 
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M. tuberculosis, M. bovis, N. 
farcinica, P. aeruginosa  
Bacterial wall (121–123) 
PCNA Up-regulated in tumour cells 
Nucleus of healthy cells, plasma 
membrane of tumour cells 
(124) 
MLL5 isoform 
HIV-infected T cells, tumour 
cells 
Plasma membrane (104,125) 
Syndecan-4 Tumour cells Plasma membrane (126) 
PDGF-DD Up-regulated in tumour cells Soluble  (127) 
HSPG 
All cells, up-regulated/ 
modified on tumour cells 





Plasma membrane (128,129) 
NKp30 
Viral HA 
Poxvirus, vaccinia virus 
infected cells 
Plasma membrane (109) 
pp65 HCMV infected cells Cytoplasm  (130) 
PfEMP-1 
P. falciparum infected 
erythrocytes 
Plasma membrane (110) 
BAT3/BAG6 Up-regulated in tumour cells 
Cytoplasm of healthy cells, 
plasma membrane and exosomes 
of tumour cells, soluble  
(131,132) 
B7-H6 Tumour cells 






Soluble  (135) 
HSPG 
All cells, up-regulated/ 
modified on tumour cells 
Plasma membrane (118) 
Table 1. Summary table of NCR ligands 




the binding of different bacterial components, CFP might facilitate the recognition of NCR bacterial 
ligands and subsequent NK cell activation essential to control bacterial infections (117). 
NKp30 ligands 
NKp30 has been shown to bind HA of Poxviruses, such as human vaccinia virus and murine ectromelia 
virus: NKp30-HA interaction impairs NKp30-mediated NK cell activation, as opposed to the activating 
role of NKp46 interaction with HA of the same viruses (109). NKp30 displays an inhibitory function also 
upon interaction with the tegument protein pp65 of HCMV, due to the dissociation of NKp30 from 
CD3 chain. Since pp65 is localised in infected cell cytoplasm, it has been proposed that NKp30 could 
interact with a pp65 soluble form released from apoptotic infected cells: this explanation is supported 
by the presence of anti-pp65 antibodies in the serum of HCMV infected patients (130). On the other 
hand, NKp30 interaction with PfEMP1 of Plasmodium falciparum expressed on parasitised 
erythrocytes results in the induction of an activating signal (110).  
The first identified NKp30 cellular ligand was HLA-B-associated transcript 3 (BAT3), also known as Bcl-
associated anthanogene 6 (BAG6), a nuclear protein involved in the p53-mediated cellular response to 
stress and DNA damage (131). Another NKp30 cellular ligand is represented by B7-H6, a 
transmembrane protein belonging to B7 family that is selectively expressed on several tumour cell 
types (such as lymphomas, leukaemia, melanoma, and carcinoma), and on monocytes and neutrophils 
upon stimulation with TLR ligands or with proinflammatory cytokines (133,136). B7-H6 expression has 
been shown to be down-regulated upon treatment of tumour cells with histone deacetylase (HDAC) 
inhibitors: this modulation results in a reduced NK cell-mediated cytotoxicity and could influence the 
outcome of anti-tumour therapies based on HDAC inhibitors (137). However, other types of cancer 
therapies, such as cysplatin and 5-fluorouracil chemotherapy, radiation therapy, and cytokine therapy 
(i.e. localised administration of TNF-), are able to induce in tumour cells a stress response that results 
in the up-regulation of B7-H6 expression and increased susceptibility to NK cell cytolysis (138). Finally, 
NKp30 has been demonstrated to bind to Galectin-3 (Gal-3), expressed by tumour cells (135). 
NKp44 ligands 
NKp44 has been demonstrated to recognise ligands of viral origin, such as HA of influenza (119), HA 
and hemagglutinin-neuraminidase (HN) of Newcastle Disease virus, and envelope glycoproteins of 
West Nile and Dengue viruses (120). In particular, NKp44 recognition of Newcastle Disease virus 
stimulates both IFN- and TNF- production and NKp44-mediated cytolytic activity. Microbial ligands 
for NKp44 are expressed on the surface of Mycobacterium family members, such as Mycobacterium 
bovis bacillus Calmette-Guérin (BCG) (121), Mycobacterium tuberculosis (122), Nocardia farcinica, and 
Pseudomonas aeruginosa (123). NKp44 interaction with BCG can induce proliferation, IFN- 




production, and NK cell cytotoxic activity (121), whereas the outcome of NKp44 interaction with the 
other Mycobacterium family members is still unclear.  
The first identified cellular ligand for NKp44 was PCNA (Proliferating Cell Nuclear Antigen), a nuclear 
protein expressed by actively replicating cells and involved in DNA repair and replication (124). PCNA 
expression increases during tumour progression and decidua development; in these conditions, it can 
be expressed on the cell membrane in association with HLA-I molecules (139). When exposed at the 
cell surface, PCNA can interact with NKp44 receptor, inducing the transduction of an inhibitory signal 
through its ITIM sequence, probably representing a mechanism of tumour escape from NK cell-
mediated killing (124). PCNA is also overexpressed in the decidua during the first trimester of 
pregnancy, as well as in a subset of decidual DCs reported to interact with dNK cells. Since dNK cells 
express higher levels of NKp44-1 than pNK cells, it was suggested that PCNA-induced NK cell inhibition 
through NKp44 could be one of the mechanisms enabling the regulatory and immunotolerant 
phenotype of dNK cells (77,124). 
More recently, another cellular ligand for NKp44 was described. Vieillard et al. observed that Human 
Immunodeficiency Virus (HIV) infected CD4+ T cells express a ligand (NKp44L) for NKp44 receptor: its 
expression is induced by the interaction of gp41 HIV protein with gC1qR (receptor for the complement 
component C1q) and is able to stimulate NK cell-mediated killing of infected T cells (125,140). 
Subsequently, this NKp44L was identified as an isoform of Mixed-Lineage Leukaemia Protein 5 (MLL5) 
nuclear protein: MLL5 splicing variant (21spe-MLL5) lacks exon 5 and contains at the C-terminal the 
21spe exon allowing the expression of this molecule at the cell surface (104).  
The expression of NKp44 ligand(s) was also observed on the surface of articular chondrocytes, but the 
nature of these ligands is still unknown. NKp44 ligand recognition may induce chondrocyte killing by 
IL-2 activated NK cells, thus contributing to cartilage destruction occurring in rheumatoid arthritis 
(128). Recently, astrocytes have been shown to express a NKp44 ligand, whose expression can be 
down-regulated by HIV infection, suggesting a viral escape mechanism (129). 
A peculiar interaction between NKp44 receptor and the HSPG syndecan-4 was described: these two 
molecules can interact in cis on the NK cell surface, regulating NKp44 surface distribution and function, 
since syndecan-4 can mask NKp44 binding site necessary for the interaction in trans with other ligands 
(126).  
Finally, PDGF-DD was recently identified as a novel NKp44 soluble ligand able to trigger NK cell-
mediated cytokine release and correlating with reduced tumour dissemination in NCR2-transgenic 
mice (127). 
Heparan sulphates proteoglycans 
Heparan sulphate proteoglycans (HSPGs) can be found attached to the cell surface and in the 
Extracellular Matrix (ECM): HSPGs, such as syndecans and glypicans, are long anionic polysaccharides 




composed of repeated disaccharide units of iduronic or glucuronic acid and glucosamine that are 
differentially sulphated at N, 2-O, 3-O and 6-O positions and are conjugated to protein structures 
(141,142). All three NCRs have been demonstrated to recognise different epitopes on HSPGs, but 
appear to preferentially bind to highly sulphated structures (two or three sulphate groups for each 
disaccharide unit) through basic amino acids on the receptor surface (118). Since tumour cells often 
display an altered heparan sulphate (HS) expression, NCRs might be able to recognise peculiar epitopes 
expressed by transformed cells. HS structures on proteoglycans could act as a bridge between NK and 
tumour cells, as supported by the observation that cells lacking HS, but not chondroitin sulphate, are 
recognised to a lesser extent, and for this reason NK cells are less efficient in killing such cellular targets 
(143). 
Recent studies focused on NCR interactions with their ligands suggest that in many cases recognition 
can be influenced by the presence of co-ligands. HLA-I and HSPGs were suggested to be co-ligands that 
could act as docking proteins able to connect NCRs to their respective ligands or to bind to other 
molecules generating complexes that are recognised by NCRs in their wholeness (105). In addition, it 
has been demonstrated that HSPGs act as co-ligands involved in the recognition of tumour cells by 
NCRs and can induce IFN- release but not NK cell-mediated cytotoxicity (118,143). HLA-I might 
represent another co-ligand, since it localizes with NCR ligands, such as PCNA and BAT3 on tumour cell 
surface (105,132,139). The involvement of these co-ligands in the interactions between NCRs and their 
ligands could also play a role in the outcome of NK cell response to a stimulus: since in some conditions 
this interaction can result in NK cell inhibition, the presence or the absence of co-ligands might favour 
an activating or an inhibitory effect on NK cells (105). 
1.1.5. Soluble ligands for NK cell receptors 
In the last years, an increasing number of soluble ligands for NK cell activating receptors have been 
described: these soluble molecules are often represented by peculiar isoforms of ligands usually 
expressed at the cell surface or cleaved forms of cell surface ligands. Many of the soluble ligands 
described until now act as decoy molecules, preventing the interaction of activating receptors with 
their ligands expressed on target cells; in other cases, soluble ligands induce down-regulation of their 
specific receptors on NK cell surface. Both mechanisms result in the inhibition of NK cell cytotoxicity, 
thus representing a strategy of tumour escape.  
Soluble ligands for NKG2D receptor have been extensively characterised. ADAM (A Disintegrin And 
Metalloprotease) and ERp5 proteases can cleave MICA/B releasing soluble forms able to induce NKG2D 
internalisation upon receptor engagement (144–146); similarly, ULBPs can be released in soluble forms 
due to the activity of ADAM10 and ADAM17 proteases and could trigger NKG2D down-regulation 
(147,148). 




Also DNAM-1 ligands can be found in soluble form. PVR splice variants may lack the transmembrane 
region: PVR and PVR, in contrast to PVR, are soluble forms whose levels can be increased in the 
serum of cancer patients. However, the biological significance of these soluble molecules, as compared 
to membrane-bound PVR, is still unclear (149–151). 
Regarding NCRs, soluble ligands for all three receptors have been identified: in the case of CFP, no 
activating effect through the interaction with NKp46 receptor has been observed (117). NKp30 
interaction with its membrane-bound ligands and subsequent transduction of activating signals are 
impaired in the presence of soluble ligands such as BAT3, B7-H6, and Gal-3. BAT3 and Gal-3 are 
released from tumour cells, whereas B7-H6 is shed in a soluble fragment through ADAM10 and 
ADAM17 proteases, which can be released in the tumour microenvironment (134). The inhibitory role 
of soluble BAT3 has been described in the case of Chronic Lymphocytic Leukaemia (CLL) (152), whereas 
soluble B7-H6 has been found to mediate NKp30 down-regulation in NK cells derived from ovarian 
cancer patients (153). It is of note that BAT3 and B7-H6 can be released not only in soluble form but 
also associated with exosomes: BAT3-containing exosomes secreted from DCs and tumour cells are 
able to induce both cytotoxicity and cytokine secretion through the interaction with NKp30 receptor. 
Due to their ability to stimulate NK cell cytotoxicity, a role for BAT3-positive exosomes derived from 
DCs in the induction of DC editing process has been suggested (131,132). NKp30 also recognises Gal-
3, a soluble protein expressed by tumour cells: Gal-3 expression has been shown to correlate with an 
increased apoptosis of tumour-associated lymphocytes and with a reduced NK cell cytotoxic activity, 
since Gal-3 is able to interfere with NKp30-mediated recognition of tumour cells (135). PDGF-DD is the 
most recently identified NCR ligand and the first documented soluble molecule recognised by NKp44 
receptor. Barrow and colleagues demonstrated that PDGF-DD recognition by NKp44 triggers IFN- and 
TNF- release by NK cells, as well as other proinflammatory cytokines involved in tumour growth 
arrest. Moreover, they observed that the spread of PDGF-DD-expressing tumour cells is limited in 
NCR2-transgenic mice as compared to non transgenic mice. Based on these data, Barrow et al. 
suggested that on one hand PDGF-DD induces tumour growth, while on the other hand it stimulates 
NK-, ILC1- and ILC3-mediated immune responses through its interaction with NKp44 (127).  
1.1.6. NK cell function in tumour immunosurveillance  
Tumour immunosurveillance is one of the most important NK cell functions, as supported by different 
observations (for example, individuals with low NK cell cytotoxic activity have a higher incidence of 
cancer). Several reports show that NK cells are able to efficiently kill tumour cells in vitro through their 
natural cytotoxic activity or through the induction of apoptosis via TNF-, FasL, and TRAIL; 
nevertheless, it has been demonstrated that such activity can be often impaired in vivo (154,155).  




In the last years an important role for NK cells in the therapy of high-risk leukaemia has been 
demonstrated (156). Haematopoietic Stem Cell Transplantation (HSCT) represents a primary therapy 
for these haematological malignancies: allogeneic HSCT is the major therapeutic option, but about 40% 
of patients does not find an HLA-matched donor; thus, an alternative source of HSCs can be obtained 
from haploidentical family members or from umbilical cord blood of unrelated subjects. In the case of 
haploidentical HSCT, patients are transplanted with HSCs from a donor that shares with the recipient 
one HLA haplotype and is mismatched for the other one: in this setting, donor HSCs can give rise to NK 
alloreactive populations, i.e. NK cells expressing KIRs specific for HLA alleles that are not expressed on 
recipient cells. In this kind of transplantation, alloreactive NK cells are essential to mediate Graft versus 
Leukaemia (GvL) effect, thus preventing leukaemia relapse. Moreover, alloreactive NK cells kill residual 
recipient DCs and T cells, preventing GvHD and graft rejection too. Several studies conducted on acute 
myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) patients confirmed that patients 
receiving grafts with alloreactive NK cells showed a significantly longer survival as compared to 
recipients of non-alloreactive grafts (156–159). These observations suggest the importance to 
overcome KIR-mediated inhibition in order to achieve full NK cell activation: based on this idea, fully 
humanised antibodies against inhibitory KIRs, such as lirilumab, have been developed and used in 
phase I and II clinical trials on AML and multiple myeloma patients (160,161). 
In the case of solid malignancies, several studies have provided evidences that a high number of 
infiltrating NK cells correlates with improved prognosis and survival probability, by preventing 
metastasis. Nevertheless, it has also been shown that during tumour progression NK cell anti-tumour 
activity can be often limited either by their inefficient migration to tumour lesions or by the inhibition 
of their functions induced by the TME (162–164).  
NK cell migration towards tumour site 
NK cell recruitment into neoplastic tissues is highly influenced by the tumour type, as well as by the 
chemokine profile in the TME: for example, in the case of CCL19, CCL21, and CXCL9-expressing 
tumours, CD56bright NK cells are likely to preferentially migrate towards the tumour site due their higher 
expression levels of CXCR3 as compared to CD56dim NK cells (162,164); notably, CD56bright NK cell subset 
can survive more easily under oxidative stress conditions often characterising tumour tissues (162). NK 
cell function and migration can be indirectly influenced by MMP and ADAM proteases, since they are 
involved in ECM remodelling, cytokine and growth factor cleavage, and ectodomain shedding of 
transmembrane proteins, including cell adhesion molecules and NK cell receptor ligands, thus 
modifying the expression of such molecules (162).  
The tumour microenvironment (TME) 
Tumour cells are characterised by deep genetic alterations that can lead to the overexpression of 
transcription factors, such as nuclear factor-B (NF-B), Signal Transducer and Activator of 




Transcription 3 (STAT3), and Hypoxia-Inducible Factor (HIF)-1, involved in promoting a favourable 
TME, characterised by an aberrant inflammation, promoting tumour cell survival, proliferation, and 
angiogenesis. Cell populations within the TME are represented by both tumour cells and tumour-
associated cells: the latter ones include TAFs, MSCs, and several immune cells with immunosuppressive 
functions, such as TAMs, Tumour-Associated Neutrophils (TANs), Myeloid-Derived Suppressor Cells 
(MDSCs), iDCs and Treg. Altogether these cells inhibit NK cell anti-tumour activity, mainly through 
modulating the cell surface expression of ligands in tumour cells and of receptors in NK cells (Fig. 4) 
(162–165). In the first case, both tumour cell genetic alterations and a process of immune selection 
through NK cell-mediated killing, especially during the initial phases of tumour development, can 
favour the selection of resistant tumour cells. Selected tumour cells often display a poor expression of 
ligands recognised by activating NK cell receptors or sometimes overexpress PCNA, whose interaction 
with NKp44 results in reduced NK cell-mediated cytotoxicity. Moreover, IFN-, GM-CSF, IL-10, and 
Leukaemia Inhibitor Factor (LIF) can induce HLA-G expression on tumour cells: HLA-G binding to the 
inhibitory receptor ILT2 on NK cells can raise the threshold for NK cell activation or induce NK cell 
apoptosis. Furthermore, HLA-G can be transferred by intercellular membrane exchange (trogocytosis) 
from APCs and tumour cells to NK cells, leading to HLA-G+ NK cells with regulatory functions (166). 
Surface expression of NK cell receptor ligands can also be modulated by tumour-derived proteases, 
which can shed surface ligands, (including B7-H6, BAT3, sMICA/B, and ULBPs), in a soluble form: these 
soluble molecules can compete with the membrane-bound ones, leading to the inhibition of NK cell 
cytotoxicity (131,134,145–148,152,153).  
The second mechanism leading to the suppression of NK cell anti-tumour activity is NK cell receptor 
down-regulation that can be induced both by soluble factors and by cell-to-cell contact. Soluble factors 
can be represented by shed NK cell receptor ligands, such as MICA/B (144), as well as by cytokines and 
metabolites (i.e. PGE2, lactate, adenosine, and galectins) produced by tumour cells and/or tumour-
associated cells (163). The main immunosuppressive cytokines within the TME are TGF-, IL-4, and IL-
10: TGF-inhibits the expression of NKp30 and NKG2D receptors, while IL-4 reduces the ability of NK 
cells to kill susceptible cellular targets, to produce cytokines, and to functionally interact with DCs 
(82,162–164,167). Several cell populations in the TME express IDO, whose metabolic activity results in 
the depletion of tryptophan (Trp), essential for immune cell functions, and promotes the production 
of the immunosuppressive Trp catabolite L-kynurenine, able to inhibit NKp46 and NKG2D expression 
(162–164). Furthermore, TAFs can inhibit NK cell functions by preventing the IL-2-induced up-
regulation of NKp44, DNAM-1, and NKp30 receptors through both cell-to-cell contact and PGE2; also 
tumour cells have been shown to inhibit NKp30, NKp44, and NKG2D expression through IDO- and 
PGE2-dependent mechanisms (73,163,164). In addition, different studies have reported that NK cells 
infiltrating the tumour display high levels of NCR inhibitory isoforms, while the expression of activating  





Figure 4. Inhibition of NK cell functions by tumour microenvironment (TME)  
Schematic representation of soluble factors and surface molecules inhibiting NK cell functions within the 
TME. 
isoforms has been correlated with a better prognosis. The expression of NKp30 a, b, and c isoforms 
has been studied in several tumours: in long-term surviving melanoma patients, higher levels of 
activating NKp30a isoform have been observed (78), whereas gastrointestinal stromal tumour (GIST) 
and metastatic neuroblastoma patients with predominant expression of NKp30c have a reduced 
survival, since they are less responsive to B7-H6+ tumour cells (75,168). Some studies showed a 
differential expression of NKp44 isoforms in NK cells infiltrating solid tumour tissues as compared to 
the ones in surrounding normal tissues: NK cells in the TME appear to express higher levels of 
potentially inhibitory NKp44-1 isoform (77). Moreover, in a recent study, Shemesh et al, observed that 
AML patients with high expression levels of NKp44-1 isoform have a poorer survival than those mainly 
expressing NKp44-2 and -3 isoforms (169). 
Within the TME, extracellular vesicles derived from tumour and tumour-associated cells have also been 
found: these vesicles, released by normal and tumour cells, are able to transfer functionally active 
proteins, lipids, and nucleic acids, and play an important role in intercellular communication in both 
physiological and pathological conditions. Extracellular vesicles can be primarily divided in exosomes, 
that are endosomal-derived nanovesicles, and microvesicles (MVs) generated by the outward budding 
from the plasma membrane (170,171). Tumour-related exosomes (TEXs) released from cancer cells 
are involved in tumour angiogenesis, ECM remodelling, tumour migration, and metastasis formation. 




Analysis of TEX derived from tumour patients, revealed that TEXs can contain immunosuppressive 
molecules, ranging from immune checkpoint receptor ligands (such as PD-L1), inhibitory cytokines (IL-
10, TGF-, and PGE2) to noncoding RNAs (172). One of the well-known mechanisms is TEX-mediated 
down-regulation of NKG2D activating receptor, but TEXs are also able to reduce expression of perforin 
and signalling pathway components, resulting in the inhibition of NK cell-mediated cytotoxicity (172). 
Hypoxia is frequently observed in TME; the hypoxic condition can be involved in the induction of 
tumour resistance and in the regulation of immunosuppressive cells (173,174). In particular, hypoxia 
has been shown to directly affect NK cell function by reducing granzyme and perforin expression levels 
and by inducing the up-regulation of HIF-1: this results in the impairment of NCR and NKG2D up-
regulation in the presence of activating cytokines including IL-2, IL-15, and IL-12 (173). Importantly, 
HIF-1 expression affects NK cell natural cytotoxicity, while it does not alter ADCC function, since CD16 
expression is not altered. HIF-1 expression impairs NK cell functions also indirectly, by down-
regulating NKG2D ligands, inducing TGF- secretion by tumour cells, increasing the number of 
infiltrating Treg and MDSCs, and favouring M2 polarisation (163,174).  
1.2. NIDOGEN-1 (NID1) 
Nodogen-1 (NID1), also called Entactin, is a sulphated glycoprotein, member of Nidogen family 
together with the closely related Nidogen-2 (NID2): Nidogens are two monomeric glycoproteins 
involved in the stabilisation of Basal Membrane (BM) and in the maintenance of ECM structure 
(175,176). NID1 and NID2 share the same basic structure composed of three globular domains (G1-3): 
the first two domains (G1 and G2) are connected by a link region, while G2 and G3 domains are 
separated by a longer rod-like region. Protein sequence analysis shows that Nidogens contain 
structural motifs that are typical of ECM proteins, such as Epidermal Growth Factor-like (EGF), 
thyroglobulin type-1 (TY), low density lipoprotein receptor (LY), NIDO, and G2 Nidogen and fibulin 
module (G2F) domains. For both proteins, a splice variant exists, lacking at least one EGF domain in 
the rod-like region. NID1 and NID2 display an overall sequence homology of about 46%, but 
comparison of the single protein motifs indicates that the sequence homology ranges from 39,5% to 
71,8% (Table 2). NID1 and NID2 main structural differences are located in the G3 domain and in the 
rod-like region, which is longer in NID2 than in NID1 (Fig. 5) (176,177). These proteins also partially 
differ for their expression in human tissues, since NID1 is ubiquitously and more abundantly expressed 
than NID2 (176). A third important difference is the presence of an RGD (Arg-Gly-Asp) sequence in the 
first EGF motif in the rod-like region of both NID1 isoforms, but not in NID2. The RGD sequence has 
been shown to be involved in the interaction of NID1 with integrins expressed on the cell surface, thus 
suggesting that NID1 may display peculiar functions (178–182).  
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Table 2. Percentage of homology between NID1 and NID2  
NID1 protein motifs are listed from the N-terminal to the C-terminal. For each motif and for the entire 
protein, the percentage of homology with the corresponding motif of NID2 is indicated. In the case of TY 
motif, the percentage of homology was calculated comparing the NID1 motif with each of the two TY NID2 
motifs of. 
 
Figure 5. The Nidogen family 
The modular structure characterising NID1, NID2, and their isoforms is shown. Both proteins display NIDO 
(Nidogen like domain), G2F (G2 Nidogen and Fibulin module), TY (Thyroglobulin type-1 module), EGF 
(Epidermal Growth Factor like module), and LY (Low density lipoprotein receptor) domains. For each 
protein the protein length is indicated. This representation is based on sequence analysis performd with 
SMART database (http://smart.embl-heidelberg.de). 
1.2.1. NID1 functions and protein interactions 
NID1 is involved in the formation and maintenance of ECM structure, especially in BM, and has been 
shown to play an important role in cellular adhesion, neutrophil chemotaxis, nerve development, and 
tumour angiogenesis (176,179,180,182–185). 
Being involved in the assembly of BM, Nidogens are able to interact with different ECM and BM 
components, such as laminin, fibrinogen, collagen IV, fibulin, and the HSPG perlecan. Several studies 
have elucidated the domains involved in such interactions: G3 domain is important for the connection 
with laminin, while G2 domain is mainly involved in the interaction with perlecan and collagen IV, 
whose binding surfaces are probably partially overlapped (176,186,187). NID1 is also able to bind 
fibulin-1 or -2, in contrast with NID2 that is, however, able to bind collagen XVIII, endostatin, and 
tropoelastin, components of elastic lamellae in the larger arteries. Interactions between MSC-released 
NID1 and epithelial cell-derived laminin are essential for maintaining ECM structure, and, thus, for 
organ development. Nevertheless, NID1 absence has no evident effect on development in NID1-




knockout mice, probably because NID2 can compensate NID1 loss; moreover, only some slight 
neurological effects in worms and mice models arise in the absence of both NID1 and NID2 (176).  
For both NID1 isoforms, interactions with cell surface proteins are possible through the RGD sequence 
that allows NID1 to bind 31 (CD49c/CD29) (178). NID1 can also interact with V3 integrin 
(CD51/CD61), but in this case a cysteine-rich EGF repeat in the G2 domain seems to be involved in the 
binding (181). Until now, studies conducted in order to elucidate the functions of these interplays 
suggest that NID1-integrin interaction is not responsible for the structural role of NID1 in the ECM; 
however, the RGD sequence in NID1 has been shown to be essential for blastocyst outgrowth and 
migration in an in vitro murine model (180). The observation that NID1 can be found in decidual tissue 
during early post-implantation development, and displays a chemotactic activity on different cell types 
(such as neutrophils), suggests that NID1 plays an important role in trophoblast adhesion and 
migration. Both trophoblast and neutrophil migration and adhesion appear to be mediated by V3 
and 31 integrins (179,182,183).  
It has been demonstrated that the membrane protein Tumour Endothelial Marker 7 (TEM7) is a ligand 
for NID1. TEM7 is mainly expressed on endothelial cells during tumour angiogenesis, but also in healthy 
tissues, such as embryonic vasculature, and in some neurons (188). NID1 has been shown to play a role 
in nerve development in a C. elegans experimental model (184); based on these findings, NID1 
involvement in Schwann cell regulation was investigated and found to exert on these cells a prosurvival 
and promigratory effect mediated by 1 integrins; this function can be blocked using a soluble TEM7 
ectodomain, probably due to competition with integrins for NID1 binding. However, a direct 
involvement of TEM7-NID1 interaction in this process has not been demonstrated (185). 
1.2.2. Role of NID1 in tumours and other diseases 
The wide NID1 binding potential, together with its high protease sensitivity might play an important 
role in the modulation of BM functions under both normal and pathological conditions. Several studies 
report an involvement of NID1 in different types of cancer and in the metastatic process. Moreover, 
some recent reports propose NID1 as a candidate biomarker for some types of neoplasia. It is well 
known that ECM structures, such as BM, play a key role in cancer metastatic processes, and that the 
up-regulation of proteases often associates with metastasis spreading. NID1 link region between G1 
and G2 domains, as well as G3 domain can be hydrolysed by serine proteases, i.e. thrombin, trypsin, 
kallikrein, and MMPs, while NID1 can acquire more resistance when forming a complex with laminin 
molecules (189). Sage et al. showed that the cysteine protease cathepsin S (CatS) can degrade NID1 as 
well as NID2: the cleavage sites are located in G2 and G3 domains, essential for NID1 interaction with 
other ECM components such as laminin; therefore, this cleavage results in an impaired NID1 binding 
to other ECM proteins (190). A more recent study showed that the previously identified CatS cleavage 




site at the level of TY domain in the rod-like region produces a specific peptide, called NIC, whose 
serum levels could be used as a biomarker in patients with Non-Small Cell Lung Cancer (NSCLC) (191). 
For both MPP-19 and ADAMTS1 (a disintegrin and metalloprotease with thrombospondin repeats 1), 
distinct studies report conflicting results, probably because of the different experimental models: it 
has been shown that these proteases can prevent neoangiogenesis, important for tumour 
development, but also that they can degrade the ECM, thus promoting tumour cell migration and 
metastatic processes (192,193).  
In the last years, several studies have described the presence of NID1 in exosomes and, in particular, 
in exosomes derived from cancer patients (194–199). NID1-positive exosomes were detected in 
urinary samples from healthy patients but also in the serum of patients with melanoma, 
nasopharyngeal carcinoma, breast cancer, and ovarian cancer; in some of these cases, NID1 has been 
proposed as a biomarker able to reflect tumour burden (199,200). Studying NID1 involvement in 
ovarian cancer, Zhou et al. observed that NID1 can promote Endothelial-Mesenchymal Transition 
(EMT), thereby potentially supporting metastasis formation in a 3 integrin-dependent manner; in 
addition, in this report, NID1-induced chemoresistance to cisplatin treatment was also observed (201). 
Aberrant expression of NID1 was detected in gastrointestinal and endometrial cancers too, but with 
opposite effects: in the first case, reduced NID1 expression resulted in the loss of BM integrity, 
favouring tumour invasion, metastasis, and angiogenesis (202), whereas in endometrial cancer, NID1 
overexpression positively correlated with tumour invasiveness (203).  
Dysregulation of Nidogen expression has been reported in various pathologies, such as Hirschsprung’s 
disease and osteoarthritis; a NID1 nonsense mutation has been associated with an autosomal 
dominant pathology, the Dandy-Walker malformation and occipital cephaloceles, characterised by 
cerebellar hypoplasia, meningeal anomalies, and occipital skull defects (204). Kruegel et al. 
demonstrated a differential expression of NID1 and NID2 in human cartilage; increased amounts of 
both proteins were observed in late-stage osteoarthritis, where they could play a role in restoring 
cartilage integrity. In this study, it has also been proposed that NID1 could be involved in inflammation 
processes of osteoarthritis due to its chemotactic activity (205). NID1 was also found to be involved in 
Hirschsprung’s disease: NID1 expression could be regulated by miR-192 and miR-215, which are down-
regulated in colon tissues of Hirschsprung patients; as a consequence, NID1 expression is up-regulated 
in these subjects. Since Hirschsprung’s disease is caused by an incorrect migration of enteric neural 
crest cells, it has been suggested that NID1 altered expression could be the cause of such incorrect 
migration (206). 
  




2. AIM OF THE STUDY 
Based on the observation that NK cell receptor ligands can be released in a soluble form by tumour 
cells concurring to tumour escape mechanisms, for the aim of the study was the search for novel NKp44 
soluble ligands. To this end, we used chimeric molecules consisting of the extracellular portion of 
different NK cell receptors fused with a mutated Fc portion of human IgG1 (Fc molecules) that cannot 
be recognised by Fc receptors. The finding of novel soluble ligands for NKp44 could be useful in order 
to better understand the interactions between NK and tumour cells, and how tumour cells either 
directly or through the modification of TME, could modulate NK cell responses. Moreover, since 
soluble ligands often represent a mechanism of tumour escape, the finding of novel released molecules 
affecting NK cell functions could have an impact also on the development of prognostic systems and, 
possibly, on the improvement of NK cell-based cancer immunotherapy. 
3. MATERIALS AND METHODS 
3.1. CELL CULTURE 
In this study the following cell lines were used: HEK293T (human embryonic kidney); K562 (human 
erythroleukemia); Bw1547 (murine thymoma); P815 (murine mastocytoma); C-32 and Mewo 
(melanoma); A172 and U87-MG (glioblastoma); LOVO and SW480 (colon cancer); GI-LI-N, GI-ME-N, 
and SH-SY5Y (neuroblastoma); LCL721.221 (B-EBV); HeLa (cervical adenocarcinoma); LNCap and PC3 
(prostate cancer); A2780 (ovarian adenocarcinoma); JEG-3 (placental choriocarcinoma). Cell lines were 
cultured either in DMEM (HEK293T) or in RPMI1640 medium supplemented with 10% Foetal Calf 
Serum (FCS), 2mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Euroclone). K562 
stable transfectants were selected and cultured in the presence of G418 sulphate (Calbiochem) at the 
final concentration of 1.2 mg/ml. 
3.2. ANTIBODIES 
The following monoclonal antibodies (mAbs), produced in our laboratory, were used in this study: 7A6 
and AZ20 (IgG1, anti-NKp30), BAB281 (IgG1, anti-NKp46), Z231 (IgG1, anti-NKp44), GN18 (IgG1, anti-
DNAM-1), L95 (IgG1, anti-PVR), KS38 (IgM, anti-NKp44), and 3C8 (IgM, anti-CD63).  
The following commercial antibodies were also used: anti-CD335 (IgG1, clone 19A1.4.9), hamster anti-
mouse CD29-PE (IgG, clone HM1-1), hamster anti-mouse CD61-PE (IgG, clone 2C.9.G2), and human 
anti-mouse CD49a-PE (IgG1, clone REA493) (Miltenyi Biotec); mouse anti-laminin -1 mAb (IgG1; clone 
D-3), mouse anti-vimentin mAb and mouse anti-Na+/K+-ATPase 1 (0.T.1) mAb (Santa Cruz 
Biotechnology); mouse anti-laminin mAb (IgG1; clone LAM-89) (Leica Biosystems); mouse anti-NID1 




mAb (IgG1; clone 302117) and goat anti-NID1 polyclonal Ab (R&D); goat anti-human IgG Horseradish 
Peroxidase (HRP)-conjugated mAb, goat anti-mouse Ig HRP-conjugated mAb, goat anti-IgM HRP-
conjugated mAb, mouse anti-goat IgG HRP-conjugated mAb, goat anti-rabbit HRP-conjugated mAb, 
and goat anti-mouse IgG1 PE-conjugated mAb (Southern Biotech); goat anti-human IgG PE-conjugated 
mAb (Jackson ImmunoResearch); goat anti-mouse IgM-AlexaFluor 647, rabbit polyclonal anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Ab (ThermoFisher); sheep anti-mouse IgG 
(GAM, MP Cappel); mouse anti-His mAb (Roche). 
3.3. PREPARATION OF CELL CULTURE SUPERNATANTS AND 
METABOLIC LABELLING 
Wild type or transfected HEK293T, K562, and Bw5147 cell lines were maintained either in medium 
supplemented with 1% FCS or in protein-free CD Hybridoma medium (ThermoFisher) for 48-72 h 
before the collection of culture supernatant (SN). When indicated, SN obtained from cell cultures in 
protein-free medium was concentrated with Amicon Ultracel-10K (Millipore) before the subsequent 
use: HEK293T-SN was concentrated up to 30-fold, while SN from wild type and transfected K562 cells 
were concentrated about 10-fold. Assessment of protein concentration of SN derived from culture in 
protein-free medium was determined using Bradford Protein Assay (Bio-Rad). 
In order to perform metabolic labelling of glycoproteins, HEK293T cells were cultured in protein-free 
medium with 40 M N-azidoacetylmannosamine-tetraacylated (ManAz) (ThermoFisher); after 72 h, 
the collected SN was concentrated about 24-fold with Amicon Ultracel-10K, then secreted 
glycoproteins containing azido-sugars were labelled with 200 M Biotin-PEG3-Phosphine 
(ThermoFisher) O/N at room temperature (r.t.). After labelling, HEK293T-SN-biot was dialysed in PBS 
(Phosphate Buffer Saline; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4), using D-Tube 
Dialyzer Maxi, MWCO 6-8 kDa (Novagen).  
3.4. PREPARATION OF SOLUBLE CHIMERIC RECEPTORS 
Chimeric Fc receptors were prepared as described in (28). The sequences encoding for the extracellular 
portion of the different receptors (NKp30, NKp44, NKp46, and DNAM-1) were subcloned in the pRB1-
2B4Fcmut vector (kindly provided by Dr. M. Falco, Ist. G. Gaslini, Genoa, Italy) in frame with the 
sequence coding for the human IgG1 Fc portion. In order to obtain a mutated Fc portion that does not 
bind to Fc receptors, three residues of the amino acid sequence were mutated as followed: L234A, 
L235E, and G237A. These constructs were stably transfected into HEK293 cell line using JetPEI 
(Polyplus) following manufacturer’s instructions, and after 48-72 h cells were selected with 0.5 mg/ml 
G418 sulphate (Calbiochem) and subcloned by limiting dilution. Cell clones were cultured either in 
DMEM/10% Ultra-low IgG FCS (ThermoFisher) or in Ex-CELL ACF CHO medium (Sigma) and the soluble 
Fc molecules released in the collected SN were purified by affinity chromatography on Protein A 




Sepharose 4 Fast Flow (Amersham Biosciences) normalised with PBS at r.t. The column was extensively 
washed with PBS and Fc molecules were eluted using 0.1 M glycine pH 3; next, Tris pH 8 at a final 
concentration of 0.1 M was used to restore the neutral pH. Fc molecules were concentrated and 
dialysed in PBS using Amicon Ultracel-30K (Millipore). The purified recombinant proteins were 
quantified using Bradford Protein Assay and checked by SDS-PAGE followed by gel staining with AgNO3, 
and by ELISA with mAbs specific for the different receptors. 
3.5. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
Control of purified Fc molecules was performed coating 5 g/ml Fc molecules diluted in PBS O/N at 
4°C and saturated using PBS/3% Bovine Serum Albumin (BSA) for 3 h at r.t.. Saturated wells were 
washed and incubated with anti-NKp30, anti-NKp44, anti-NKp46, or anti-DNAM-1 mAbs for 1 h at r.t. 
followed by HRP-conjugated mAb.  
In direct ELISA experiments, 100 l of concentrated SN derived from HEK293T cells cultured in protein-
free medium, 5 g/ml recombinant human proteins (rNID1 or rNID2 (R&D), or HMGB1), exosomes, or 
MVs were diluted in PBS and coated on ELISA plates O/N at 4 °C. Recombinant HMGB1, obtained in 
the baculovirus system, was kindly provided by Dr. Marco Pedrazzi (Dept. Experimental Medicine, 
University of Genoa, Italy). After saturation, samples were incubated with 1 g/ml mouse anti-NID1 or 
anti-CD63 mAbs, or with Fc molecules at the final concentration of 10 g/ml (except when otherwise 
indicated), followed by HRP-conjugated secondary reagents.  
Indirect ELISA were performed using ELISA plates coated with Fc molecules or mouse anti-NID1 mAb 
(5 g/ml diluted in PBS), saturated, and incubated with 100 µl HEK293T-SN-biot or with SN of NID1-
transfected or wild type HEK293T, K562, and Bw5147 cells cultured in medium with 1% FCS or in 
protein-free medium. HEK293T-SN-biot was then incubated with HRP-conjugated Streptavidin 
(Southern Biotech); alternatively, incubation with HEK293T, K562, and Bw5147 transfectant-derived 
SN was followed by incubation with 0.5 g/ml polyclonal goat anti-NID1 Ab and HRP-conjugated anti-
goat IgG mAb.  
Competition experiments were performed on ELISA plates coated with 5 g/ml rNID1, saturated, and 
incubated with 1 g/ml Fc molecules, followed by 0.5 g/ml goat anti-NID1 Ab and mouse anti-goat 
HRP-conjugated mAb. 
For all ELISA experiments, the HRP substrate ABTS (2,2′-azino-di-(3-ethylbenzthiazoline sulfonic acid) 
(Roche) was used and the colorimetric reaction was measured with a microplate reader (TECAN 
Sunrise) at an optical density (O.D.) of 405 nm. 
3.6. CELL LYSIS AND MEMBRANE PREPARATION 
Cells were lysed in 1% Nonidet P-40 (NP-40, Sigma) in a buffer containing 150 mM NaCl, 10 mM Tris-
HCl (pH 7.5), 1 mM MgCl2, and protease inhibitor cocktail cOmplete (Roche).  




For cell membrane preparations, cells were pelleted and lysed with 3 volumes of 0.25 M sucrose, 10 
mM Tris-HCl pH 7.4, 5 mM EDTA, and protease inhibitor cocktail cOmplete and subsequently sonicated 
(100% amplitude 1 cycle) for 30’’ for 4 times using VialTweeter (Hielscher). Next, samples were 
centrifuged at 500 g x 10’ and the pellet containing nuclei was discarded, while the supernatant was 
centrifuged again at 7,500 g x 20’ in order to remove the pellet containing cellular organelles contained 
in the pellet. Supernatant was then ultracentrifuged at 100,000 g x 1 h (Beckman OptimaTM Max-E) and 
the pellet containing cell membranes was washed twice and resuspended in PBS. Protein 
concentration of cell lysates and membrane preparations was determined using Bradford Protein 
Assay. 
3.7. SDS-PAGE AND WESTERN BLOT ANALYSIS  
For the control of Fc molecules, 2 g of each sample and control mouse IgG (Sigma) were diluted in 
sample buffer (10% glycerol, 2% SDS, 62.5 mM Tris-HCl pH 6.8, 0.01% bromophenol blue) with the 
addition of 5% -mercaptoethanol (Sigma) for 5’ at 100 °C. Samples were separated by SDS-PAGE on 
10% polyacrylamide gel using Tris-Glycine running buffer (4.25 M Tris-HCl pH 7.5, 2 M glycine, 1% SDS); 
gel was then subjected to silver staining.  
For western blot experiments the following amounts of samples were used: 100 g of cell lysates and 
membrane preparations, 28 g or 30 l of protein-free or RPMI/1% FCS SN, respectively, 160 ng of 
rND1, 20 g of ECM (Sigma), Matrigel (BD Biosciences), exosomes, or MVs, or 0.2 g of purified human 
laminin (Millipore). Samples were run on 7.5% or 10% polyacrylamide gel under non-reducing 
conditions and transferred to Immobilon-P PVDF membranes (Millipore). Immunoprecipitated 
samples, exosomes, and MVs were run on gel prepared with 7.5% TGX Stain-Free Acrylamide Solutions 
(Bio-Rad). Membranes were blocked with 5% BSA in Tris-buffered-saline containing 0.05% Tween-20 
(TBS-T) and probed with 0.7 g/ml anti-NID1 mAb, mouse anti-CD63 mAb, mouse anti-laminin -1 mAb 
(1:200, Santa Cruz Biotechnology), rabbit anti-GAPDH Ab (1:5,000), or Fc molecules (7 g/ml) followed 
by the appropriate HRP-conjugated secondary reagent. The SuperSignal West Pico Chemiluminescent 
Substrate (ThermoFisher) was used for detection. Images were acquired with ChemiDoc Touch Imaging 
System (Bio-Rad) and analysed with Image Lab software (Bio-Rad). 
3.8. SILVER STAINING 
Silver staining of Fc molecules separated by SDS-PAGE was performed through subsequent incubation 
of the gel in the following solutions: A solution (50% methanol, 12% CH3COOH) for 30’; B solution (20% 
ethanol, 10% CH3COOH) for 20’; B solution/0.4 mM KMnO4 for 15’; 0.7 mM K2CO3 for 15’; H2O for 5’; 
15 mM AgNO3 for 15’; H2O for 5’; developing solution (0.1 M K2CO3, 0,01% formaldehyde); fixing 
solution (1% CH3COOH) for 10’. 




3.9. TWO-DIMENSIONAL ELECTROPHORESIS (2-DE) AND 
WESTERN BLOT 
Concentrated HEK293T-SN and HEK293T-SN-biot (300 g for Western blot and 600 g for preparative 
gels) were solubilised in the reduction/alkylation solution containing 8 M urea, 4% CHAPS, 5 mM 
tributylphosphine, 20 mM iodoacetamide (IAA), 40 mM Tris, and 0.1 mM EDTA for 3 h. To prevent 
over-alkylation during the isoelectro focusing (IEF) step, excess of IAA was neutralised by adding an 
equimolar amount of DTT. Finally, samples were dissolved in the focusing/re-hydratation solution, i.e. 
7 M urea, 2 M thiourea, 4% CHAPS, and 15 mM dithioerythritol and a 0.6% carrier ampholyte cocktail, 
containing 40% of the pH 3.5–10 and 60% of the pH 4–8 intervals (BDH Biochemicals) and loaded onto 
home-made non-linear pH 3-10 strips (207). After IEF runs, the strips were equilibrated in 6 M Urea, 
50 mM Tris-HCl pH 8.8, 2% SDS, 30% glycerol, and trace of bromophenol blue and the proteins were 
separated using a SDS-PAGE (T% 8–16) and transferred onto nitrocellulose membranes (Protean BA85, 
Whatman) with a semidry system. The membranes were saturated with 3% polyvinyl-pyrrolidone in 
TBS and incubated overnight separately with NKp44Fc, NKp30Fc, NKp30Fc, NKp46Fc in 3% BSA in TBS-
T 0.15%. Then, membranes were rinsed in TBS-T and incubated with anti-human IgG HRP-conjugated 
antibody or Neutravidin-HRP (ThermoFisher). For preparative experiments, SDS-gels were stained with 
“blue silver” colloidal Coomassie (208). Images were digitalised using GS-800 scanner (Bio-Rad) and 
analysed with PDQuest advance 8 software (Bio-Rad). 
3.10. MASS SPECTROMETRY  
Spots excised from 2D-PAGE were fully discoloured and digested with trypsin. All mass spectrometric 
measurements were performed using a LTQ linear ion trap mass spectrometer (Thermo Electron) 
coupled to a HPLC Surveyor (Thermo Electron) equipped with a Jupiter C18 column 250 mm × 1 mm 
(Phenomenex). Protein identification was performed using SEQUEST software and searched against a 
Human protein database. Peptide MS/MS assignments were filtered following very high stringent 
criteria: Xcorr ≥1.9 for the singly charged ions, Xcorr ≥2.2 for doubly charged ions, Xcorr ≥3.7 for triply 
charged ions, peptide probability ≤0.01, delta Cn ≥0.1 and Rsp ≤4.26. 
Polyclonal IL-2-activated NK cells derived from four different healthy donors were incubated for 21 h 
at 37 °C in FCS- and IL-2-deprived medium in the presence or absence of the following stimuli: directly 
coated rNID1 (20 g/ml) or anti-NKp44 mAb coated via GAM. Next, cells were collected and lysed for 
subsequent proteomic analysis. Samples were processed by in-StageTip processing method, containing 
2 SDB-RPS disks (209). 25 L of 2% SDC, 10 mM TCEP, 40 mM CAA and 100 mM Tris pH 8.5 were added 
to the pellets and the cells were lysed, reduced, and alkylated in a single step and then loaded into 
StageTip. The lysates were diluted with 25 mM Tris pH 8.5 containing 1 µg of trypsin. Samples were 
acidified with 100 µl of 1% TFA and washed three times with 0.2 % TFA. Elutions were performed with 




60 µl of 5% ammonium hydroxide, 80% ACN. Samples were loaded from the sample loop directly into 
a 75-m ID × 50 cm 2 m, 100 Å C18 column mounted in the thermostatated column compartment 
and the peptides were separated with increasing organic solvent at a flow rate of 250 nl/min using a 
non-linear gradient of 5-45 % solution B (80% CAN and 20% H2O, 5% DMSO, 0.1% FA) in 180’. Eluted 
peptides were analysed using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific 
Instruments). Orbitrap detection was used for both MS1 and MS2 measurements at resolving powers 
of 120 K and 30 K (at m/z 200), respectively. Data dependent MS/MS analysis was performed in top 
speed mode with a 2 sec. cycle time, during which precursors detected within the range of m/z 
375−1500 were selected for activation in order of abundance. Quadrupole isolation with a 1.8 m/z 
isolation window was used, and dynamic exclusion was enabled for 30s. Automatic gain control targets 
were 2.5 × 10E5 for MS1 and 5 × 10E4 for MS2, with 50 and 54 ms maximum injection times, 
respectively. The signal intensity threshold for MS2 was 1 × 104. HCD was performed using 28% 
normalised collision energy. One microscan was used for both MS1 and MS2 events. 
MaxQuant software (210) (version 1.6.0.1), was used to process the raw data, setting a false discovery 
rate (FDR) of 0.01 for the identification of proteins, peptides and PSM (peptide-spectrum match), a 
minimum length of 6 amino acids for peptide identification was required. Andromeda engine, 
incorporated into MaxQuant software, was used to search MS/MS spectra against Uniprot human 
database (release UP000005640_9606 February 2017). In the processing the variable modifications 
are Acetyl (Protein N-Term) Oxidation (M), Deamidation (NQ), on the contrary the Carbamidomethyl 
(C) was selected as fixed modification. The intensity values were extracted and statistically evaluated 
using the ProteinGroup Table and Perseus software. Algorithm MaxLFQ was chosen for the protein 
quantification with the activated option ‘match between runs’ to reduce the number of the missing 
proteins. 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE76 partner repository with the dataset identifier PXD008252. Project Name: Nidogen-1 is 
a novel extracellular ligand for the NKp44 activating receptor. Project accession: PXD008252. Reviewer 
account details: Username: reviewer37086@ebi.ac.uk Password: P4JxwhXj. 
3.11. IMMUNOPRECIPITATION 
Immunoprecipitation experiments were performed with 12 µg NKp44Fc, NKp30Fc, or DNAM-1Fc 
molecules linked to Dynabeads Protein G (ThermoFisher) and incubated O/N at 4 °C with 500 g 
concentrated HEK293T-SN. Elution was carried out for 5’ at 60 °C using non-reducing sample buffer. 
3.12. TRANSIENT AND STABLE CELL TRANSFECTANTS  
HEK293T cells were transiently transfected with pcDNA3.1-NID1 (Geneart) or with the empty vector 
(mock) using JetPEI following manufacturer’s instructions. After 24 h the culture medium was replaced  




by DMEM/1% FCS or by protein-free medium and SN were collected after 72 and 120 h.  
Similarly, K562 cell line was transfected with pcDNA3.1 vector encoding for NID1 using JetPEI; after 72 
h 1.2 mg/ml G418 sulphate was added to the culture medium in order to select stably transfected cells. 
At the end of the selection period, surviving cells were subcloned by limiting dilution.  
NID1 was cloned from pcDNA3.1-NID1 into pMXs-IG (IRES-GFP) retroviral vector (kindly provided by 
Dr. Kitamura, Tokyo, Japan). Alternatively, NKp44 ORF and DAP12 ORF cDNAs were cloned in the two 
available cloning sites of pMXs-IG vector (GFP-encoding sequence was replaced by DAP12 ORF cDNA). 
The pMXs-IG-NID1 and pMXs-IG-NKp44/DAP12 constructs were transiently transfected into Plat-E 
packaging cell line in order to generate viral particles that were used to infect Bw5147 cells. NID1-
positive cells were sorted according to GFP expression, while Bw-NKp44 cells were sorted based on 
NKp44 expression. Both cell lines were subcloned by limiting dilution. Bw-NKp30 cells, expressing a 
chimeric molecule composed of the extracellular region of NKp30 fused to murine CD3, were kindly 
provided by Eric Vivier (Marseille, France).  
3.13. RT-PCR ANALYSIS 
Total RNA was extracted from different cell lines using RNAeasy Mini Kit (Qiagen). Oligo(dT)-primed 
cDNA was prepared starting from 1 g of RNA using Transcriptor First Strand cDNA Synthesis Kit 
(Roche) following manufacturer’s instructions. RT reaction was conducted for 10’ at 42 °C followed by 
50’ at 55 °C. PCR reactions were carried out for 30 cycles utilising Platinum TAQ DNA Polymerase 
(ThermoFisher) at an annealing temperature of 58 °C (-actin) or 62 °C (NID1). Primers used were: -
actin for 5’ ACTCCATCATGAAGTGTGACG and -actin rev 5’ CATACTCCTGCTTGCTGATCC; NID1 for 5’ 
CTCCATTGGGCCTGTGAGG and NID1 rev 5’ AGACACGGGGGCGTCATC. PCR products were separated by 
electrophoresis on a 1.5% agarose gel and visualised by ethidium bromide staining (PCR product 
length: 249 bp-actin, 795 bp NID1 isoform 1, 396 bp NID1 isoform 2). 
3.14. FUNCTIONAL ASSAYS ON BW5147 CELL 
TRANSFECTANTS 
Bw-NKp44 and Bw-NKp30 cells were pre-treated for 1 h at 37 °C with 20 or 7.5 g/ml rNID1 or rNID2, 
or with 100 l SN obtained from K562 or Bw5147 transfectants cultured in RPMI/1% FCS. Pre-treated 
cells were plated on 96-well cell culture plates (1x105 cells/well) coated with 5 g/ml GAM alone or 
GAM plus 5 g/ml anti-NKp44 or -NKp30 mAbs (except when indicated); alternatively, Bw5147 call 
transfectants were stimulated with 25 or 250 ng/ml rPDGF-DD (R&D) upon pre-treatment. For co-
culture experiments, Bw cells were incubated for 1 h at 37 °C with wild type or NID1-transfected K562 
or Bw cells at an effector-target (E:T) ratio of 1:1 and then transferred on mAb-coated plates. For 
stimulation experiments, 1x105 Bw-NKp44 cells were plated on cell culture plates directly coated with 
5 g/ml of rNID1 or indirectly coated using 5 g/ml mouse anti-NID1 or mouse anti-His mAbs followed 




by rNID1. After 21 h stimulation at 37 °C, SN were collected and analysed for their IL-2 content by ELISA 
using the Mouse IL-2 ELISA Ready-SET-Go kit (eBioscience) following manufacturer’s instructions. The 
range of quantification for the assay was 2-200 pg/ml. Each sample was run in duplicate. 
3.15. GENERATION OF POLYCLONAL NK CELLS 
NK cells were purified from peripheral blood of healthy donors using the RosetteSep™ NK Cell 
Enrichment Cocktail (StemCell Technologies). Cell populations displaying more than 95% of CD56+CD3-
CD14- NK cells were selected. Purified NK cells were cultured on irradiated feeder cells in the presence 
of 100 U/mL rhIL-2 (Proleukin, Novartis) and 1.5 ng/mL phytohemagglutinin (Gibco Ltd) in round-
bottomed 96-well microtiter plates. After 3/4 weeks of culture the expanded NK cells were used for 
functional experiments. 
3.16. FUNCTIONAL ASSAYS ON POLYCLONAL NK CELLS 
NK cell-mediated cytotoxicity against Bw and Bw-NID1 transfected cells or against the P815 FcR+ cells 
was evaluated in a 4 h 51Cr-release test. In the redirected killing assay against P815 cells, mAbs were 
used as hybridoma supernatants (appropriately titrated to induce specific functional response in NK 
cells). 100 l of K562-SN or K562-NID1-SN were added on NK cells 1 h before the onset of the test. 
For the IFN- secretion assay, 1x105/well NK cells were pre-treated with 100 l K562-SN or K562-NID1-
SN and cultured O/N on GAM-coated wells either in the absence or in the presence of the indicated 
mAbs; alternatively, pre-treated NK cells were stimulated with 50 or 250 ng/ml rPDGF-DD. Culture 
supernatants were then collected and analysed for the presence of IFN- using the IFN gamma Human 
ELISA kit (ThermoFisher). 
3.17. FLOW CYTOMETRY  
Cells were incubated with primary mAbs (50 l of hybridoma SN or 1 g/ml anti-NID1 mAb) or Fc 
molecules (20 μg/ml) in PBS/2% FCS for 30’ at 4 °C, washed with 0.9% NaCl/2% FCS, and stained with 
the appropriate phycoerithrin (PE)- or AlexaFluor 647-conjugated isotype-matched secondary mAbs 
for 30’ at 4 °C. For intracellular staining, cells were fixed with PBS/4% formaldehyde and permeabilised 
with PBS/0.01% NP-40 prior incubation with primary mAbs. Bw-NKp44 and Bw-NKp30 cell 
transfectants were incubated with PE-conjugated anti-integrin antibodies for 30’ at 4 °C. For double 
immunofluorescence staining, NK cells were incubated for 1h at 4 °C with 100 l of wild type or 
transfected HEK293T-derived SN obtained from cell culture in protein-free medium; next mAbs were 
added in the following order: anti-NID1, goat anti-mouse IgG1 PE-conjugated, anti-NKp44 IgM, and 
goat anti-mouse IgM-AlexaFluor 647 mAbs. All samples were analysed using a FACSCalibur flow 
cytometer and Kaluza software (Beckman Coulter).  




3.18. IMAGING FLOW CYTOMETRY  
HEK293T cells were incubated with anti-NID1 mAb followed by PE-conjugated anti-mouse IgG1 mAb. 
Prior to analysis, cells were stained with the nuclear dye Hoechst 33342 (ThermoFisher). Cells were 
acquired with a 12 channel MultiMag system ImageStreamX Mark II imaging flow cytometer (IFC) 
(Merck) using INSPIRE acquisition software (Amnis Corporation). Three ImageStream channels were 
used: channel 1 for the brightfield, channel 3 for NID1-PE (excited by a 488 nm laser), channel 7 for 
Hoechst44432 (excited by a 405 nm laser). In order to collect only focus-single-cells, we first restricted 
our analysis on the brightfield (BF) parameters analysis. Single cells were selected using a biparametric 
dot plot representing BF aspect ratio (i.e. width/height) versus BF cell area then, by mean of the BF 
gradient RMS (root mean square), which measures the sharpness quality of an image, we gated only 
on focus cells. For each staining condition, 4,000 raw images were collected using a 40x objective. To 
avoid spectral overlaps, single-colour compensation controls (500 cells each) were gathered and a 
compensation matrix was generated. 
The raw image files were then analysed using IDEAS 6.0.3 software (Amnis Corporation) setting 
compensation on the basis of the calculated matrix. To verify the correspondence between data 
derived from traditional cytometry and IFC, we compared NID1 expression with its negative control 
(i.e. cells labelled only with secondary PE-conjugated antibodies) by mean of their MFI (mean 
fluorescence intensity). To grant a better visualization of these data, we merged the two files. 
3.19. SILENCING EXPERIMENTS 
NID1 expression was transiently silenced in HEK293T cells by siRNA transfection using iBONi siRNA 4-
duplexes Plus sense 5’-UAAACCAUCUUGUCCACGCCCCC-3’ and antisense 5’-
GGGGGCGUGGACAAGAUGGUUUA-3’ siRNA-NID1 (ID4811_4) and sense 5’-
ACAACAUUCAUAUAGCUGCCCCC-3’ and antisense 5’-GGGGGCAGCUAUAUGAAUGUUGU-3’ siRNA-CTR 
(iBONi Negative Control-N3) (Riboxx Life Sciences). Cells were transfected with 300 nM siRNA using 
Amaxa Cell Line Nucleofector Kit V (Lonza) and analysed by flow cytometry after 48 and 72 h for NID1 
expression. Alternatively, 50 nM siRNA were transfected in HEK293T cells with Interferin (Polyplus) 
following manufacturer’s instructions and after 72 h SN obtained from cells cultured in protein-free 
medium were collected, concentrated, and analysed by Western blot with anti-NID1 mAb and NKp44Fc 
followed by appropriate HRP-conjugated secondary reagents. 
3.20. ISOLATION OF EXTRACELLULAR VESICLES  
Extracellular vesicles were isolated from SN of HEK293T cells cultured in DMEM with exosome-
depleted FCS. FCS was depleted from exosomes by ultracentrifugation at 140,000 g for 2 h at 16 °C. 
For the isolation of extracellular vesicles, SN was first centrifuged at 16,000 g to remove cell debris and 
mitochondrial fraction; the microvesicles (MVs) were then isolated from the 16,000 g supernatant by 




centrifugation at 22,000 g in a JA-20 rotor (Beckman Avanti™ J-25) O/N at 16 °C. The 22,000 g pellet 
was washed 3 times with 1 ml of PBS each time and centrifuged at 16,000 g for 10 min at 4 °C to remove 
any proteins. The 22,000 g supernatant was ultracentrifuged at 100,000 g in a Ti 90 rotor (Beckman 
Optima™ l-90K) O/N at 18 °C to pellet the exosomes. The pellet was treated as described above. The 
amount of proteins in exosomes and microvesicles was measured using Quant-iT Protein Assay Kit for 
Qubit fluorometer (ThermoFisher); prior to quantification, exosomes and microvesicles were 
incubated for 10’ at 60 °C in 2% SDS in order to lyse the vesicles. 
3.21. DOT BLOT 
0.2 g of purified human laminin or 20 g of concentrated HEK293T-SN were spotted on nitrocellulose 
membrane (Whatman), saturated with TBS/5% BSA and subsequently stained with mouse anti-laminin 
mAb (1:200, Leica Biosystems) or with 7 g/ml Fc molecules followed by the appropriate HRP-
conjugated secondary mAbs. The SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher) 
was used for detection. Images were acquired with ChemiDoc Touch Imaging System (Bio-Rad) and 
analysed with Image Lab software (Bio-Rad). 
3.22. STATISTICAL ANALYSES  
Data were analysed using GraphPad Prism 6 by non-parametric two-tailed Mann-Whitney test or by 
non-parametric one tailed Wilcoxon test. A p value of less than 0.05 (*), 0.01 (**), or 0.001 (***) was 
considered statistically significant. Data obtained from mass spectrometry experiments were analysed 
with R or Perseus software. 
4. RESULTS 
4.1. CHARACTERISATION OF SOLUBLE LIGAND(S) FOR NKp44 
RECEPTOR 
In order to identify novel NKp44 soluble ligand(s), we selected HEK293T cell line as experimental 
model, since flow cytometry analysis, performed with NKp44Fc on a panel of different cell lines, 
revealed that HEK293T cells could express NKp44 ligand(s). Moreover, these cells can be easily cultured 
in protein-free medium, essential in order to obtain cell culture SN containing only proteins released 
from cultured cells. To this end, HEK293T-SN was collected after 72 h cell culture in protein-free 
medium; subsequently, it was concentrated and used in direct ELISA experiments to test NKp44Fc 
reactivity against coated HEK293T-SN. Our results indicated within HEK293T-SN the presence of 
soluble ligand(s) for NKp44Fc and NKp46Fc chimeric receptors, while no reactivity was observed with 
neither NKp30Fc nor DNAM-1Fc (Fig. 6A). With the aim of further characterising NKp44 soluble 




ligand(s), we analysed HEK293T-SN by SDS-PAGE and immunoblotting using different Fc molecules: 
NKp44Fc and NKp46Fc were the only chimeric molecules interacting with HEK293T-SN, as already 
observed in ELISA experiments (Fig. 6B). Notably, NKp44Fc clearly identified a band of approximately 
180 kDa, in contrast with NKp46Fc that weakly recognised multiple bands at different molecular 
weights. Finally, as secreted proteins are frequently glycosylated, we investigated whether NKp44 
ligand(s) could be represented by glycoproteins. To this end, we collected SN of HEK293T cell line 
cultured in the presence of protein-free medium supplemented with modified sugars (i.e. azido-
sugars). Cultured cells can uptake the azido-sugars from the medium and employ them to glycosylate 
proteins; moreover, the presence of an azido group allows the conjugation of labelled glycoproteins 
with biotin. 
 
Figure 6. Reactivity of different Fc molecules with HEK293T-SN  
A) HEK293T-SN-coated ELISA plates were incubated with the indicated Fc molecules followed by HRP-
conjugated anti-human IgG mAb. Graph represents the absorbance at 405 nm after normalization to 
background (nonspecific binding of the HRP-conjugated mAb). Data are medians ± interquartile range of 
three independent experiments performed in triplicate, dots represent single values; ****p<0.0001 by 
two-tailed Mann-Whitney test. (B) Concentrated HEK293T-SN was loaded in each lane and analysed by 
SDS-PAGE on a 7.5% polyacrylamide gel. Samples were immunoblotted with the indicated Fc molecules 
followed by HRP-conjugated anti-human IgG mAb. One representative experiment of three is shown. (C) 
HEK293T-SN-biot or HEK293T-SN, as negative control, was incubated on NKp44- or NKp30-coated ELISA 
plates followed by HRP-conjugated Streptavidin. Graph represents the absorbance at 405 nm after 
normalization to background (nonspecific binding of the HRP-conjugated Streptavidin). Data are medians 
± interquartile range of three independent experiments performed as duplicates, dots represent single 
values; **p=0.0022, ns (not significant)=0.0606 by two-tailed Mann-Whitney test. 
 Next, biotin-tagged soluble glycoproteins contained in HEK293T-SN (HEK293T-SN-biot) were 
concentrated and incubated on NKp44Fc- or NKp30Fc-coated ELISA plates, followed by HRP-




conjugated Streptavidin. Results indicated that NKp44Fc could recognise soluble glycoprotein(s), while 
no reactivity was detected in NKp30-coated wells (Fig. 6C).  
4.2. IDENTIFICATION OF A NKp44 CANDIDATE LIGAND 
Once established that NKp44 could recognise soluble glycosylated protein(s) at high MW, we combined 
two-dimensional electrophoresis (2-DE) and mass spectrometry analyses in order to identify such 
ligand(s). Proteins contained in HEK293T-SN and HEK293T-SN-biot were resolved by 2-DE and 
subsequently immunoblotted with different Fc molecules or HRP-conjugated Neutravidin, respectively 
(Fig. 7A-D). Notably, 2-DE analysis of HEK293T-SN with distinct Fc molecules revealed a stronger 
reactivity of all Fc molecules than that observed in the previously shown mono-dimensional SDS-PAGE: 
we hypothesise that this different reactivity might reflect differences in experimental procedures. Fig. 
7E shows a preparative gel in which HEK293T-SN proteins were stained with Blue Coomassie: from this  
 
Figure 7. Analysis of HEK293T-SN and HEK293T-SN-biot by two-dimensional electrophoresis (2-DE)  
(A, B, C) Concentrated HEK293T-SN was analysed by 2-DE and, after blotting, membranes were stained 
with NKp44Fc (A), NKp30Fc (B), or NKp46Fc (C) followed by HRP-conjugated anti-human IgG mAb. (D) 2-
DE separation was applied to concentrated HEK293T-SN-biot and the membrane was probed with HRP-
conjugated Neutravidin. (E) HEK293T-SN proteins, separated by 2-DE, were stained with “blue silver” 
colloidal Coomassie. Spots excised for the subsequent mass spectrometry analysis are numbered from 1 
to 27; spot 26 is highlighted with a red circle in panels (A), (D), and (E). 





Table 3. Proteins identified in 27 selected spots analysed by mass spectrometry 
Proteins are grouped according to the spots in which they were identified. For each protein, name, 
accession number, gene name, MW, calculated pI, glycosylation, coverage, score, unique peptides, and 
total peptides are indicated. The symbol ‘+’ indicates the presence of glycosylation according to protein 
databases. Underlined proteins derive from glycosylated spots; bolded proteins have been identified in 
spots specifically stained by NKp44Fc; Nidogen-1 is highlighted in red. 










gel, 27 spots corresponding to those visualised also in NKp44Fc blot were excised and analysed by mass 
spectrometry (Table 3). Next, by comparison with blot stained with NKp30Fc, NKp46Fc, and 
Neutravidin, we selected nine spots specifically recognised by NKp44Fc and containing glycosylated 




proteins. Among these spots, we focused our attention on spots 26 and 27, corresponding to high MW 
proteins: within spot 26 we selected NID1 as a candidate ligand for NKp44 receptor.  
4.3. NKp44 CAN INTERACT WITH NID1 
In order to investigate whether NID1 could be specifically recognised by NKp44Fc in different 
conditions, we initially performed immunoprecipitation experiments from HEK293T-SN using 
NKp44Fc, NKp30Fc, and DNAM-1Fc molecules; immunoprecipitated samples were separated by SDS-
PAGE under non-reducing conditions. Subsequent immunoblotting with anti-NID1 monoclonal 
antibody (mAb) revealed that NID1 was immunoprecipitated by NKp44Fc, but not by NKp30Fc nor by 
DNAM-1Fc (Fig. 8A). In addition, we performed mass spectrometry analysis, confirming the presence 
of NID1 in NKp44-immunoprecipitated samples and its absence in NKp30Fc and DNAM-1Fc 
immunoprecipitates (Table 4). Since NID1 is a BM component, we next analysed two commercial 
solubilised BM preparations, ECM (Sigma-Aldrich) and Matrigel (BD Bioscience): as expected, and in 
accordance with previously published data (211), Western Blot analysis confirmed the presence of 
NID1 in both preparations. In particular, anti-NID1 mAb identified two different bands, probably 
representing NID1 cleaved forms, due to the presence of proteases within ECM and Matrigel. 
Interestingly, in both samples NKp44Fc recognised a band of about 80 kDa, possibly corresponding to 
a proteolytic product of NID1 (Fig. 8B). Immunoprecipitation experiments performed on ECM with 
different Fc molecules and analysed by mass spectrometry confirmed that NKp44Fc, but not other Fc 
molecules, could bind NID1. Interestingly, we also detected ADAMTS1 protease within NKp44Fc 
immunoprecipitates from both ECM and HEK293T-SN (Table 4), supporting the idea that NID1 
degradation products could derive from NID1 cleavage by proteases, such as ADAMTS1, MMP-2, MMP-
9, and urokinase, which are components of basement membrane-like matrix (211).  
In order to specifically assess the interaction between NKp44Fc and NID1, we used a recombinant form 
of NID1 (rNID1). Fig. 8C shows that NKp44Fc, but not NKp30Fc nor DNAM-1Fc, recognised rNID1 in 
Western Blot experiments carried out under non-reducing conditions. rNID1 was also utilised in ELISA 
experiments: the recombinant protein was coated to ELISA plates and subsequently incubated with 
scalar concentrations of different Fc molecules, ranging from 2,5 to 80 g/ml: also in this conditions, 
NKp44Fc was the only Fc molecule able to bind rNID1 (Fig. 8D). Finally, we performed competition 
experiments incubating NKp44Fc or NKp30Fc on rNID1-coated ELISA plates, followed by anti-NID1 Ab 
and its specific HRP-conjugated secondary antibody. We observed a reduction of anti-NID1 Ab binding 
in the presence of NKp44Fc as compared to control conditions (Fig. 8E), suggesting that NKp44Fc could 
compete with anti-NID1 Ab for NID1 binding.  
Taken together, these results indicate that NKp44 could interact with denatured NID1, and more 
importantly, recognise NID1 also in its native conformation. In addition, these observations suggest 




that NKp44 binds a linear epitope of NID1 and, thus, that also NID1 fragments cleaved by proteases 
could be recognised by NKp44 receptor. 
 
Figure 8. Specific recognition of NID1 by NKp44Fc soluble receptor  
(A) HEK293T-SN immunoprecipitated with the indicated Fc molecules was analysed by 7.5% SDS-PAGE 
under non-reducing conditions together with concentrated HEK293T-SN, as positive control. After 
blotting, the membrane was probed with mouse anti-NID1 mAb followed by HRP-conjugated anti-mouse 
IgG mAb. (B) Matrigel, ECM, and HEK293T-SN samples were separated by 10% SDS-PAGE and, after 
blotting, the membrane was stained with anti-NID1 or NKp44Fc followed by HRP-conjugated anti-mouse 
IgG or anti-human IgG mAb, respectively. (C) HEK293T-SN and rNID1 were analysed by SDS-PAGE on a 
7.5% polyacrylamide gel under non-reducing conditions and, after blotting, stained with the indicated Fc 
molecules or with anti-NID1 mAb, followed by HRP-conjugated anti-human or anti-mouse IgG, 
respectively. One representative experiment of three (A and B) or five (C) is shown. (D) rNID1-coated ELISA 
plates were incubated with scalar doses of the indicated Fc molecules followed by HRP-conjugated anti-
human IgG mAb. (E) NKp44Fc or NKp30Fc, as negative control, were incubated on rNID1-coated ELISA 
plates, subsequently goat anti-NID1 Ab was added followed by HRP-conjugated anti-goat IgG mAb. Graphs 
represent the absorbance at 405 nm after normalization to background (nonspecific binding of the 
secondary reagent). Data are medians of triplicates ± interquartile range and are the pooled results of 
three independent experiments, in (D) dots represent single values; ****p<0.0001 by two-tailed Mann-
Whitney test. 




Experiment NID1 ADAMTS1 Protein Score Peptides Coverage 
IP NKp44Fc from SN + + 
NID1 25.03 8 10.50 
ADAMTS1 54.03 8 15.10 
Total ECM + - 
NID1 508 33 40.40 
ADAMTS1 - - - 
IP NKp44Fc from ECM + + 
NID1 68.82 17 19.84 
ADAMTS1 10.10 1 1.91 
IP NKp30Fc from ECM - - - - - - 
IP DNAM-1Fc from ECM - - - - - - 
 
Table 4. Summary table of samples analysed by mass spectrometry  
The symbols ‘+’ and ‘-’ indicate the presence or the absence of the protein, respectively. Score, number of 
identified peptides, and the sequence coverage are indicated for each identified protein.  
4.4. PRODUCTION AND ANALYSIS OF NID1 TRANSFECTANTS 
In order to further support our observations, we decided to investigate whether a correlation exists 
between NKp44Fc binding and NID1 expression, utilising cell transfectants as a model. In particular, 
we analysed NID1 expression both in total cell lysates and in SN obtained from different NID1 
transfectants (Figs. 9-11). Since FCS contains NID1, the experiments were performed by culturing cells 
in medium supplemented with 1% FCS, in order to reduce the possible interference of NID1 
contaminants, or, alternatively, in protein-free medium. At first, we transiently transfected HEK293T 
cells (already expressing NID1) with an expression vector containing NID1 cDNA or with an empty 
vector (mock) as control. Western blot analysis performed with anti-NID1 mAb both in cell lysates and 
in non concentrated SN obtained from transfectants cultured in protein-free medium revealed an 
increase of NID1 levels in HEK293T-NID1 samples; moreover, NKp44Fc staining indicated the presence 
of a band of approximately 180 kDa in NID1-trasfected cell lysates and in the corresponding SN (Fig. 
9A-B). In contrast with the results displayed in Fig. 8C, only a weak signal was detected in HEK293T-SN 
using anti-NID1 mAb (Fig. 9A): this discrepancy is due to the fact that in the former experiment 
concentrated HEK293T-SN was used, whereas in the latter one SN was not concentrated. For the same 
reason, NKp44Fc did not reveal any band in non concentrated HEK293T-SN (Fig. 9B). SN derived from 
HEK293T-transfected cells was also analysed by ELISA: when ELISA plates were coated with anti-NID1 
mAb and subsequently incubated with SN followed by an anti-NID1 polyclonal Ab, a positive signal was 
detected only in the wells incubated with HEK293T-NID1-SN (Fig. 9C), confirming an increased 
secretion of NID1 by NID1-transfected cells. More importantly, we performed sandwich ELISA in which 
NKp44Fc- or NKp30Fc-coated ELISA plates were incubated with SN derived from transfected and wild 
type cells, followed by anti-NID1 Ab. In this experimental setting, we obtained a positive result only 
when HEK293T-NID1-SN was incubated on NKp44Fc-coated wells (Fig. 9D). Similar results were 
obtained when SN from HEK293T transfectants cultured in DMEM/1% FCS was utilised (data not 
shown). 





Figure 9. NID1 protein expression in HEK293T NID1- transfected cells and in the corresponding SN  
(A, B) Total cell lysates (A) and SN (B) derived from HEK293T and the corresponding NID1 and mock 
transfectants cultured in protein-free medium were analysed in SDS-PAGE on a 10% and 7.5% 
polyacrylamide gel, respectively; membranes were probed with NKp44Fc molecule, mouse anti-NID1, or 
rabbit anti-GAPDH Abs followed by the appropriate HRP-conjugated secondary mAb. One representative 
experiment of three is shown. (C, D) SN obtained from HEK293T transfectants cultured in protein-free 
medium were incubated on ELISA plates coated with mouse anti-NID1 mAb (C) or the indicated Fc 
molecules (D), followed by goat anti-NID1 Ab and HRP-conjugated anti-goat IgG Ab. Graphs represent 
absorbance at 405 nm after normalization to background (nonspecific binding of goat anti-NID1 plus 
secondary reagent). Data are medians of triplicates ± interquartile range and are the pooled results of 
three independent experiments, dots represent single values. ****p<0.0001, *p=0.0239 and **p=0.0093 
by two-tailed Mann-Whitney test. 
Next, we produced NID1 stable transfectants; to this end, we chose two different recipient cells that 
did not express NID1 mRNA: human K562 and murine Bw5147 cell lines (Figs. 10-11). NID1 expression 
in K562 transfectants was confirmed both at the mRNA and protein levels. Fig. 10A shows NID1 mRNA 
expression in wild type and NID1-transfected K562 cells. By Western blot and ELISA, NID1 protein 
expression was demonstrated in both total cell lysates and concentrated SN derived from K562-NID1 
cells but not from wild type cells. It is of note, however, that K562 transfectants expressed lower NID1 
levels as compared to HEK293T-NID1 cells: this could explain why we were not able to detect NID1 in 
total cell lysates using NKp44Fc (Fig. 10B). K562-NID1 transfectants were cultured in protein-free 
medium and because of the relatively low NID1 protein levels, the collected SN were concentrated 
before analysis: Western blot on concentrated K562-NID1-SN revealed NID1 expression both with anti-
NID1 mAb and with NKp44Fc (Fig. 10C). In addition, in line with results obtained with HEK293T-NID1-
SN, sandwich ELISA revealed NID1 in K562-NID1-SN but not in K562-SN (Fig. 10D-E). 




Similar experiments were performed with Bw-NID1 transfected cells cultured in RPMI/1% FCS, 
demonstrating that NID1 could be de novo expressed and released in stably transfected cells (Fig. 11A-
D).  
 
Figure 10. NID1 mRNA and protein expression in K562 cell line and transfectants  
(A) NID1 mRNA expression was assessed by RT-PCR in wild type and NID1-transfected K562 cells. Primers 
specific for -actin were utilised as positive control. PCR products were run on 1.5% agarose gel and 
visualised by ethidium bromide staining. One representative experiment of three is shown. (B, C) Total 
cell lysates (B) and concentrated SN (C) derived from K562 and the corresponding NID1 transfectants 
cultured in protein-free medium were analysed in SDS-PAGE on 10% and 7.5% polyacrylamide gel, 
respectively; membranes were probed with NKp44Fc molecule, mouse anti-NID1, or rabbit anti-GAPDH 
Abs followed by the appropriate HRP-conjugated secondary mAb. One representative experiment of three 
is shown. (D, E) Concentrated SN obtained from K562 cell transfectants cultured in protein-free medium 
was incubated on ELISA plates coated with mouse anti-NID1 mAb (D) or the indicated Fc molecules (E), 
followed by goat anti-NID1 Ab and a HRP-conjugated anti-goat IgG Ab. Graphs represent absorbance at 
405 nm after normalization to background (nonspecific binding of goat anti-NID1 plus secondary reagent). 
Data are medians of triplicates ± interquartile range and are the pooled results of three independent 
experiments; dots represent single values. ****p<0.001 by two-tailed Mann-Whitney test.  
4.5. SOLUBLE NID1 INHIBITS NK CELL FUNCTIONS 
Having demonstrated NID1 recognition by NKp44, we evaluated the functional effects induced by 
soluble NID1 (sNID1) through NID1-NKp44 interaction. To this end, we utilised an experimental model 
consisting of Bw5147 transfectants expressing either NKp44/DAP12 receptor complex (Bw-NKp44) or 
chimeric NKp30-CD3 receptor (Bw-NKp30): receptor cross-linking with specific mAbs induces IL-2 
release, which can be assessed by ELISA. Since different soluble ligands for activating NK cell receptors 
have been described to interfere with the transduction of activating signals, we investigated a possible 
inhibitory effect exerted by rNID1 on IL-2 release by Bw-NKp44 and Bw-NKp30 cells. The experiment 
was carried out by pre-treating cells with 20 g/ml rNID1 and stimulating them by mAb-mediated 
receptor crosslinking. Pre-treatment with rNID1 could inhibit IL-2 release by Bw-NKp44 cells stimulated 
with two different anti-NKp44 mAb concentrations; in this experimental setting, however, rNID1 could  





Figure 11. NID1 mRNA and protein expression in Bw5147 cell line and transfectants  
(A) NID1 mRNA expression was assessed by RT-PCR in Bw5147 cells and in the corresponding NID1 
transfectants. Primers specific for -actin were utilised as positive control. PCR products were run on 1.5% 
agarose gel and visualised by ethidium bromide staining. One representative experiment of three is 
shown. (B, C) Total cell lysates (B) and SN (C) derived from Bw5147 cells and the corresponding NID1 
transfectants were analysed by SDS-PAGE on a 10% and 7.5% polyacrylamide gel, respectively; 
membranes were probed with mouse anti-NID1 or rabbit anti-GAPDH Abs followed by the appropriate 
HRP-conjugated secondary mAbs. One representative experiment of two is shown. (C) SN obtained from 
Bw5147 cell transfectants cultured in RPMI/1% FCS was incubated on ELISA plates coated with mouse 
anti-NID1 mAb, followed by goat anti-NID1 Ab and HRP-conjugated anti-goat IgG Ab. Graph represents 
absorbance at 405 nm after normalization to background (nonspecific binding of goat anti-NID1 plus 
secondary reagent). Data are medians of triplicates ± interquartile range and are the pooled results of 
three independent experiments; dots represent single values. ****p<0.0001 by two-tailed Mann-Whitney 
test.  
also inhibit cytokine release induced in Bw-NKp30 cells by NKp30 triggering, even if at a lesser extent 
and only at the highest concentration of anti-NKp30 mAb tested (Fig. 12A). Next, the effect of two 
different rNID1 doses on IL-2 release induced by the highest mAb concentration was investigated. Fig. 
12B shows that both rNID1 doses were able to inhibit NKp44-mediated IL-2 release, while only the 
highest concentration of rNID1 decreased IL-2 release in Bw-NKp30 cells.   
As different studies reported the interaction between NID1 and V3 and 31 integrins (178,181) 
we analysed the expression levels of some integrins on Bw5147 transfectants in order to rule out a 
possible side effect of NID1 through integrins differentially expressed between the two cell 
transfectants. Fig. 13 shows the expression of CD29 (1 integrin), CD49a (3 integrin), and CD61 (3 
integrin) on Bw5147 transfectants, indicating no statistically significant differences between the two 
cell lines (Fig. 13B) and suggesting that integrins were not influencing our functional experiments. 
Next, we investigated whether also NID1-containing cell culture SN could exert an inhibitory effect on 
cytokine release. To this end, Bw-NKp44 and Bw-NKp30 cells were incubated with K562-NID1-SN 
obtained from cells cultured in RPMI/1% FCS, and subsequently stimulated with anti-NKp44 or anti-
NKp30 mAbs. The evaluation of IL-2 levels revealed that pre-treatment with K562-NID1-SN specifically 





Figure 12. Effect of rNID1 pre-treatment on NKp44-induced IL-2 production in Bw-NKp44 cells  
(A) Bw-NKp44 and Bw-NKp30 cells were left untreated or pre-treated with rNID1 (20 g/ml) and 
subsequently incubated on plates coated with two different concentrations of anti-NKp44 or anti-NKp30 
mAb. (B) Bw-NKp44 and Bw-NKp30 cells were left untreated or pre-treated with rNID1 (20 or 7.5 g/ml) 
and subsequently incubated on anti-NKp44 or anti-NKp30 mAb-coated plates. Graphs represent IL-2 
release (pg/ml) evaluated by ELISA. The background (from GAM-stimulated cells) was subtracted for each 
value. Data are medians of duplicates ± interquartile range and are the pooled results of three 
independent experiments. **p=0.0022, ns=0.0649 (A); **p=0.0022, ns=0.584 (B)) by two-tailed Mann-
Whitney test. 
 
Figure 13. Integrin expression in Bw-NKp44 and Bw-NKp30 cell transfectants  
(A) Bw-NKp44 and Bw-NKp30 cells were stained with PE-conjugated anti-CD29, anti-CD49a, and anti-CD61 
mAbs and subsequently analysed by flow cytometry. One representative experiment of three is shown. 
(B) MFI data obtained from flow cytometry analysis are represented as medians ± interquartile range of 
three independent experiments; dots represent single values. ns=0.25 by two-tailed Wilcoxon test. 
inhibited NKp44-induced, but not NKp30-induced cytokine release (Fig. 14A). Similar results were 
obtained pre-treating Bw-NKp44 and Bw-NKp30 cells with SN derived from Bw-NID1 cells (Fig. 14B).  
Having evaluated NID1 effects in a simplified experimental system, we asked whether a similar effect 
could be exerted also on NK cells. Human NK cells, obtained from different healthy donors and cultured 
in IL-2 in order to induce NKp44 expression, were incubated with K562-NID1-SN or with K562-SN as 
control. As shown in Fig. 15A, NK cell-mediated IFN-release, induced by stimulation through NKp44 
receptor, was inhibited by K562-NID1-SN, but not by control SN. It is of note that IFN- secretion 
induced by anti-NKp46 or anti-NKp30 mAb stimulation was not impaired by K562-NID1-SN. 
Subsequently, we assessed whether sNID1 could also affect NK cell cytotoxicity through the interaction 
with NKp44: to this end, NK cells pre-treated with K562-NID1-SN were utilised in a P815-redirected 
killing assay. Pre-treatment with NID1-containing SN inhibited NK cell cytotoxicity against P815 cells in 
the presence of anti-NKp44 mAb, while it was ineffective in the presence of anti-NKp30 or anti-NKp46 
mAbs (Fig. 15B).  





Figure 14. Effect of NID1-containing SN on NKp44-induced IL-2 production in Bw-NKp44 cells 
(A, B) Bw-NKp44 and Bw-NKp30 cells were left untreated or pre-treated with SN derived from 
untransfected or NID1-transfected K562 (A) or Bw5147 (B) cells and subsequently incubated on anti-
NKp44 or anti-NKp30 mAb-coated plates. Graphs represent IL-2 release (pg/ml) evaluated by ELISA. The 
background (from GAM-stimulated cells) was subtracted for each value. Data are medians of duplicates ± 
interquartile range and are the pooled results of four (A) or three (B) independent experiments; dots 
represent single values. ***p=0.0002, ns=0.1044 (A); **p=0.0022, ns=0.8983 (B) by two-tailed Mann-
Whitney test. 
 
Figure 15. Effect of sNID1 on NK cells  
(A) Polyclonal NK cells were pre-treated with SN derived from wild type or NID1-transfected K562 cells 
and subsequently cultured on plates coated with anti-NKp44, -NKp30, or -NKp46 mAbs. IFN- release was 
evaluated by ELISA. Data are medians ± interquartile range of six independent experiments performed on 
NK cells derived from three healthy donors. *p=0.0156, ns=0.1094 (NKp30) and ns=0.0983 (NKp46) by 
one-tailed Wilcoxon test. (B) Polyclonal NK cells were incubated with SN derived from wild type or NID1-
transfected K562 cells, and their cytotoxic activity against P815 target cells in the presence of anti-NKp44, 
anti-NKp30, or anti-NKp46 mAbs was evaluated. Data are represented as percentage of lysis and are the 
medians ± interquartile range of six different experiments conducted on NK cells derived from three 
different healthy donors. *p=0.0313 (2:1 ratio) and *p=0.0156 (1:1 ratio).  
In order to further evaluate whether NID1 could bind NKp44 receptor expressed at the NK cell surface, 
NK cells were incubated with SN derived from HEK293T-NID1 transfectants and stained with anti-NID1 
and anti-NKp44 mAbs. This double staining revealed that NK cells did not express NID1 at the cell 




surface and that HEK293T-NID1-SN could bind NK cells; data shown in Fig. 16 suggest that SN-derived 
NID1 could bind to NK cells displaying the highest NKp44 expression levels.  
 
Figure 16. Binding of sNID1 on NK cells 
Polyclonal NK cells were incubated with SN derived from wild type, mock-transfected, and NID1-
transfected HEK293T cells and stained with both anti-NID1 and anti-NKp44 mAbs, followed by PE-
conjugated anti-mouse IgG1 and Alexa Fluor 647-conjugated anti-mouse IgM mAb. Density plots 
represent the fluorescence intensity of anti-NKp44 (x-axis) and anti-NID1 (y-axis) mAb staining. One 
representative experiment of three, performed on NK cells from three different donors, is shown. 
Recently, PDGF-DD was identified as a novel soluble ligand for NKp44 receptor. PDGF-DD has been 
shown to induce a robust cytokine production through NKp44 engagement, whereas no effect on NK 
cell-mediated cytotoxic activity has been observed (127). These novel findings prompted us to 
investigate whether NID1 could inhibit PDGF-DD-induced cytokine secretion. To this end, Bw-NKp44 
were pre-treated with two different concentrations of rNID1 or with K562-NID1-SN and subsequently 
stimulated with 25 or 250 ng/ml PDGF-DD. Fig. 17A shows that sNID1 interfered with PDGF-DD by 
reducing PDGF-DD-induced IL-2 production; as expected, PDGF-DD did not induce IL-2 production in 
Bw-NKp30 cells. Similar experiments were performed also on polyclonal NK cells, demonstrating that 
also in this case sNID1 was able to inhibit PDGF-DD-mediated IFN- production (Fig. 17B). These 
observations sustained the idea that NID1 could act as a decoy ligand by interfering with the interaction 
between NKp44 and its specific ligands, such as PDGF-DD, thus reducing NKp44-mediated IFN- 
release. 
4.6. CELLULAR LOCALISATION OF NID1 
Several studies described NID1 interaction with integrins (178,181); nevertheless, none of them clearly 
demonstrated NID1 expression at the cell surface by immunofluorescence experiments; for this reason 
we decided to analyse more thoroughly NID1 localisation. At first, we analysed total cell lysates and 
membrane preparations from HEK293T cell line by Western blot, revealing the presence of NID1 in 
both samples; indeed, enhanced NID1 levels were detected in membrane-enriched preparations (Fig. 
18A); in parallel, immunoblotting with anti-Na+/K+ ATPase and anti-GAPDH Abs confirmed the 
enrichment in membrane proteins. To directly assess NID1 expression on the plasma membrane, we 
performed cytofluorimetric assays with a NID1-specific mAb: analysis of HEK293T cell line revealed the 
expression of NID1 at the cell surface; in parallel, NID1-negative K562 cells were analysed. As expected, 





Figure 17. sNID1 inhibits PDGF-DD-mediated cytokine release 
(A) Bw-NKp44 and Bw-NKp30 cells were pre-treated with rNID1 (7.5 or 20 g/ml) or with SN derived from 
wild type or NID1-transfected K562 cells, and subsequently stimulated with rPDGF-DD at 25 or 250 ng/ml. 
(B) Polyclonal NK cells were pre-treated with SN derived from wild type or NID1-transfected K562 cells 
and subsequently stimulated with rPDGF-DD at 50 and 250 ng/ml. Graphs represent IL-2 (A) or IFN- (B) 
concentrations evaluated by ELISA; in (A) the background from GAM-stimulated or unstimulated cells was 
subtracted. Data are medians ± interquartile range and are the pooled results of three independent 
experiments performed as duplicates (A) or six independent experiments performed on NK cells derived 
from three healthy donors (B). *p=0.0152, **p=0.0022, ns>0.9999, by two-tailed Mann-Whitney test (A); 
*p=0.0156, *p=0.0325 (K562-SN vs. K562-SN-NID1 PDGF-DD 50 ng/ml), ns=0.2188 by one-tailed Wilcoxon 
test (B). 
NID1-specific mAb did not stain these cells, neither at the cell surface nor in the cytoplasm (Fig. 18B). 
Subsequently, NID1 surface expression on HEK293T cells was confirmed by imaging flow cytometry; 
data shown in Fig. 18C-D indicated a reproducible signal obtained through NID1-specfic mAb staining. 
We decided to further confirm our observations by investigating whether NKp44 could recognise 
membrane-bound NID1 (mNID1). To this end, we performed experiments with K562-NID1 and Bw-
NID1 stable transfectants: both anti-NID1 mAb and NKp44Fc bound to K562-NID1 and Bw-NID1 but 
not to the corresponding wild type cells (Fig. 19A).  
Next, we silenced NID1 expression in HEK293T cells and analysed NID1 expression after 24 and 72 h: 
Fig. 19B shows that staining with both NKp44Fc and anti-NID1 mAb was reduced in the presence of 
siRNA-NID1 but not of siRNA-CTR. NID1 silencing was also confirmed in HEK293T total cell lysates and 




in the corresponding SN by Western blot experiments (Fig. 19C-D). These data confirm that NID1 is 
able to interact not only with sNID1 but also with mNID1. 
 
Figure 18. Analysis of NID1 surface expression in HEK293T cell line and in NID1 cell transfectants  
(A) HEK293T total cell lysate and membranes were run on a 10% polyacrylamide gel and subsequently 
immunoblotted with mouse anti-NID1, mouse anti-Na+/K+-ATPase, and rabbit anti-GAPDH Abs followed 
by the appropriate HRP-conjugated secondary reagents. One experiment representative of three is 
shown. (B) Surface or intracytoplasmic staining of HEK293T cells was performed with mouse anti-NID1 or 
mouse anti-vimentin mAbs followed by PE-conjugated anti-mouse IgG1 mAb; grey profiles represent 
isotype control. (C, D) HEK293T cells were stained with a NID1-specific mAb followed by PE-conjugated 
anti-mouse IgG1 mAb. Next, cells were incubated with Hoechst 33342 nuclear dye and analysed by Amnis 
ImageStream. NID1 expression on individual single cells is shown in (C), while histograms in (D) represent 
the overall fluorescence intensity of NID1-stained HEK293T cells as compared to isotype control. Data 
show representative images from one experiment out of three performed 
Finally, a panel of human tumour cell lines was analysed, not only for NID1 mRNA and protein levels in 
cell lysates, but also for NID1 cell surface expression (Table 5 and Fig. 20). These experiments showed 
that NID1 can be expressed by several tumour cell types, although its expression levels are highly 
heterogeneous, also among cell lines belonging to the same histotype. 
Several reports demonstrated that NID1 can be released in exosomes: NID1-positive exosomes have 
been detected in urinary samples of healthy subjects, as well as in the blood of tumour patients  (194–
199). Several ligands for activating NK cell receptors can be released in exosomes, sometimes acting 
as decoy molecules and representing a possible mechanism of tumour escape (136,212), in other cases 
(i.e. BAT3-positive exosomes) stimulating NK cell response (131,132). Based on these finding, we 




investigated whether NID1 could be released in HEK293T-derived microvesicles (MVs) and/or 
exosomes and whether, in this form, it could be recognised by NKp44Fc. To this end, HEK293T cells 
were cultured in medium supplemented with serum deprived of exosomes, and SN was collected after 
72 h, in order to purify extracellular vesicles (i.e. MVs and exosomes). Western blot analysis of 
HEK293T-derived MVs and exosomes revealed that exosomes were particularly enriched in NID1 as 
compared to MVs and that NKp44Fc was able to recognise a band with a MW corresponding 
approximately to that of NID1 (Fig. 21A). Next, we performed ELISA experiments on intact HEK293T- 
derived exosomes and MVs, in order to verify whether NID1 could be expressed on the vesicle surface. 
 
Figure 19. NKp44Fc recognises membrane-bound NID1 
(A, B) K652, K562-NID1 (A), Bw, and Bw-NID1 (B) cells were stained with a mouse NID1-specific mAb or 
with NKp44Fc followed by the appropriate isotype-matched PE-conjugated secondary mAb. Samples were 
analysed by flow cytometry. One representative experiment of four is shown. (C) HEK293T cells were 
transfected with siRNA NID1 or siRNA CTR and after 48 and 72 h were analysed by flow cytometry with 
anti-NID1 or NKp44Fc followed by the appropriate PE-conjugated secondary mAb. (D, E) HEK293T cell 
lysates (D) and SN (E) obtained from cells transfected with siRNA NID1 or siRNA CTR were analysed by 
Western blot on 10% or 7.5% polyacrylamide gels. Samples were immunoblotted with mouse anti-NID1 
mAb, rabbit anti-GAPDH Ab, or with NKP44Fc molecule followed by the appropriate HRP-conjugated 
secondary mAb. One experiment representative of three is shown.  
To this end, intact exosomes and MVs purified from HEK293T cells were coated on ELISA plates and 
incubated with NKp44Fc, NKp30Fc, anti-NID1 mAb, or with anti-CD63 mAb as positive control. Fig. 21B 
shows that NID1 was exposed on the surface of both exosomes and MVs. This observation indicates 
that NID1-positive extracellular vesicles could mediate functional effects on NK cells through their 




interaction with NKp44 receptor. Further studies are currently ongoing in order to elucidate the 
functional role of this interaction. 
Cell line mRNA Cell lysate Cell surface 
  anti-NID1 anti-NID1 NKp44Fc 
Melanoma 
Mewo + + + + 
C-32 + + + + 
Glioblastoma 
A172 + + - + 
U87-MG + + - + 
Colon cancer 
LOVO + - - + 
SW480 + + + + 
Neuroblastoma 
GI-LI-N + + + + 
GI-ME-N + + - + 
SH-SY5Y + + + + 
B-EBV 
LCL721.221 + + + + 
Cervical adenocarcinoma 
HeLa + + + + 
Prostate cancer 
LNCap - - - + 
PC3 - - - + 
Ovarian adenocarcinoma 
A2780 + + - + 
Placental choriocarcinoma 
JEG-3 + + + + 
 
Table 5. Summary table of NID1 expression on the analysed tumour cell lines belonging to different 
histotypes  
For each tumour cell line, NID1 expression at the mRNA level, in total cell lysates, and at the cell surface 
is indicated, together with NKp44Fc reactivity analysed by flow cytometry. 
 
Figure 20. NID1 expression on human tumour cell lines 
The indicated cell lines were stained with a NID1-specific mAb or with NKp44Fc followed by the 
appropriate isotype-matched PE-conjugated secondary mAb. Samples were analysed by flow cytometry. 
Grey profiles correspond to isotype control. One representative experiment of three is shown. 





Figure 21. Analysis of NID1 expression in exosomes and microvesicles derived from HEK293T cells  
(A) Exosomes (exo), microvesicles (MV) and concentrated SN derived from HEK293T cells cultured in 
DMEM supplemented with exosome-deprived FCS or in protein-free medium, respectively, were analysed 
by SDS-PAGE on a 7.5% polyacrylamide gel. Samples were immunoblotted with NKp44Fc, mouse anti-
NID1 or anti-CD63 Abs followed by the appropriate HRP-conjugated secondary mAbs. One representative 
experiment of three is shown. (B) HEK293T-derived exosomes and MVs from cell cultured in DMEM 
supplemented with exosome-deprived FCS were coated on ELISA plates. Subsequently, coated wells were 
incubated with the indicated Fc molecules, goat anti-NID1 or mouse anti-CD63 Abs followed by the 
appropriate HRP-conjugated secondary mAbs. Graph represents absorbance at 405 nm after 
normalization to background (nonspecific binding of secondary reagent). Data are means of triplicates ± 
SD and are the pooled results of three independent experiments. ****p<0.0001 by two-tailed Mann-
Whitney test. 
4.7. EFFECT OF MEMBRANE-BOUND NID1 (mNID1) 
Since NID1 can be exposed at the cell surface, we investigated whether mNID1 could exert any 
functional effect on Bw-NKp44 cell line and on polyclonal NK cells. Several studies have demonstrated 
that activating NK cell receptor ligands can be found both as surface-associated molecules and released 
as soluble proteins, inducing different effects on NK cell functions. For example, it has been shown that 
MICA/B, B7-H6, and BAT3 are able to induce NK cell activation when expressed on the surface of 
tumour cells, whereas they inhibit NK cell functions if released in soluble form (134,144,152). To 
evaluate the potential effect of mNID1, we performed co-culture experiments, in which Bw-NKp44 
cells were incubated with NID1-transfected K562 or Bw5147 cells, and observed that NID1 expression 
did not modify basal IL-2 release (Fig. 22A-B). However, in this experimental setting an inhibitory effect 
of sNID1 released by NID1 cell transfectants, counteracting a possible activation by mNID1, cannot be 
excluded. In order to mimic mNID1, we performed experiments in which rNID1 was used as a stimulus: 
Fig. 22C shows that rNID1, coated on the plate either directly or through anti-NID1 or anti-His mAbs, 
did not affect IL-2 release by Bw-NKp44 cells.  
In similar experiments, NK cells were stimulated on rNID1-coated wells: in keeping with what we 
observed in Bw-NKp44 cells, no induction of IFN- production was detected in rNID1-stimulated NK 
cells (Fig. 22D). Next, we tried to assess the effect of mNID1 on NK cell-mediated cytotoxicity; NID1-




transfected Bw cells were used as target cells, in order to avoid the interference of ligands for activating 
NK cell receptors expressed by K562 cell line. In this assay, NID1 released by Bw cell transfectants is 
less likely to interfere, since co-culture of NK cells with target cells lasts for only few hours. The analysis 
of NK cells derived from five healthy donors revealed that NK cell cytotoxic activity against Bw-NID1 
cells was slightly increased, as compared to control cells, only at the effector-target (E:T) ratio of 5:1 
(Fig. 22E). Nevertheless, the analysis of selected donors characterised by NK cells with a low cytotoxic 
activity against Bw cells, allowed to observe a statistically significant increase of NK cell cytotoxicity 
against Bw-NID1, as compared to wild type cells, at the different E:T ratios tested (Fig. 22F).     
 
Figure 22. Functional effects of cell surface-associated NID1 or plastic-bound rNID1 in Bw-NKp44 and 
in NK cells  
(A, B) Bw-NKp44 cells were cultured alone or in the presence of wild type or NID1-transfected K562 or 
Bw5147 cells. IL-2 release in the SN was evaluated by ELISA. Data are medians of duplicates ± interquartile 
range and are the pooled results of three independent experiments. ns=0.5714 by two-tailed Mann-
Whitney test. (C) Bw-NKp44 cells were incubated on plates coated with rNID1, anti-NID1 + rNID1, or anti-
His + rNID1. IL-2 release in the SN was evaluated by ELISA. Data are medians of duplicates ± interquartile 
range and are the pooled results of two independent experiments. ns=0.8286 (-) or ns=0.6571 (anti-NID1, 
anti-His) by two-tailed Mann-Whitney test. (D) Polyclonal NK cell lines were incubated on plates coated 
with rNID1. IFN- release in the SN was evaluated by ELISA. Data are medians ± interquartile range of 8 
independent experiments with 3 different donors. ns=0.2305 by one-tailed Wilcoxon test. (E, F) NK cell 
cytotoxicity was evaluated against Bw and Bw-NID1 transfected cells. Data are represented as percentage 
of lysis and are the medians ± interquartile range of fifteen (D) or 9 (E) independent experiments 
conducted on 5 (E) or 2 (F) different healthy donors. *p=0.0277 (D), *p=0.0371 (20:1) and 0.0373 (10:1 
and 2.5:1) (E) by one-tailed Wilcoxon test.  
4.8. EFFECT OF NID1 STIMULATION ON NK CELL PROTEOMIC 
PROFILE 
Our data showed that mNID1 induced only a slight increase of NK cell cytotoxicity and did not alter 
cytokine production. To gain further hints about the possible effect of NID1 on NK cell functions, we 




stimulated NK cells from four healthy donors on NID1- or anti-NKp44 mAb-coated plates and 
subsequently performed a proteomic analysis of NK total cell lysates by high-resolution mass 
spectrometry. Data analysis through the MaxQuant software allowed the identification of 6903 total 
proteins, of which 5682 were quantified using a Label-Free Quantitation approach. Most of them (i.e. 
5317 proteins) could be found in all samples, whereas only a small part was specific for each condition 
(Fig. 23A). Bioinformatic analysis showed that rNID1 as well as anti-NKp44 mAb stimuli modified NK 
cell proteomic profile, as compared to their corresponding control. Venn diagram of the identified 
proteins from stimulated and control samples revealed that 1663 and 1431 proteins were commonly 
down- or up-regulated, respectively, by both treatments (Fig. 23B), indicating that NID1 and NKp44 
stimulations could result in the concordant modulation of a huge number of proteins. Instead, 69 and 
84 proteins, were exclusively up- and down-regulated by NID1 treatment, respectively, while 91 and 
123 proteins were selectively up- and down-regulated in NKp44-stimulated NK cells (Fig. 23B).  
 
Figure 23. Venn diagram showing protein profile overlap between rNID1- and anti-NKp44 mAb-
stimulated NK cells  
(A) Venn diagram of total proteins identified in NK cells stimulated with rNID1 or anti-NKp44 mAb and 
their controls, CTR and GAM, respectively. The number of common and exclusive proteins is indicated in 
the respective overlapping and not-overlapping areas. (B) Venn diagram represents up- and down-
regulated proteins by rNID1 or anti-NKp44 mAb stimulation in NK cells as compared to their controls. 
Numbers in not-overlapping areas indicate proteins exclusively identified in the rNID1vsCTR or 
NKp44vsGAM datasets. 
Subsequently we focused our attention on statistically significant modulated proteins: two-sample t-
test analysis, represented as volcano plots, indicated 112 proteins statistically regulated by NID1 
treatment (Fig. 24A) and 129 by NKp44 stimulation (Fig. 24B); among them, only 15 proteins were 
common to both conditions.  
In order to investigate the cellular processes modulated by NID1 stimulation, we performed a GO 
analysis of biological processes and cellular components: results indicated that NK cell stimulation with 
rNID1 induced the modulation of several biological processes, including cell proliferation, signal 
transduction, endo/exocytosis, immune response, and, in particular, cell metabolism (Fig. 25A-B). 





Figure 24. Proteomic analysis of NK cells stimulated with rNID1 or anti-NKp44 mAb  
(A, B) Volcano plots represent differentially expressed proteins in rNID1-stimulated vs. not stimulated 
(CTR) NK cells (A) or anti-NKp44 mAb-stimulated vs. not stimulated (GAM) NK cells (B). Black line indicates 
FDR=0.05 and s0=0.1; coloured squares are not statistically significant proteins, dots represent proteins 
with a statistically significant modulation specific for anti-NKp44 or NID1 stimuli, black asterisks represent 
statistically significant proteins common to anti-NKp44 and NID1 stimuli. Magnitude of fold-change is 
represented on the x-axis (proteins up-regulated after treatment are shown on the right, the down-
regulated ones on the left); y-axis represents statistical significance (-log10 of p value).  




Since many of these biological processes were modulated also by NKp44 mAb-mediated NK cell 
stimulation, we analysed the biological processes and molecular functions modulated by the two 
stimuli as compared to their respective control. Fig. 25C shows a heatmap describing the modulation 
 
Figure 25. GO analysis of proteomic data obtained by NID1- and NKp44- stimulated NK cells  
(A, B) GO classification based on biological processes (A) or cellular component (B) of proteins 
significantly modulated by rNID1 and anti-NKp44 mAb stimuli. (C) The output matrix contains a list of 
GO terms whose expression values have a statistically significant preference to be systematically larger 
or smaller than the overall distribution of expression values. GO terms were subsequently clustered 
based on such “enrichment profiles” using the simple Euclidian-distance–based average-linkage 
hierarchical clustering. 




of NK cell proteotype in response to NID1 or anti-NKp44 stimuli: such analysis revealed that the two 
stimuli have partially overlapping effects on NK cell proteomic profile. 
To summarise, these data suggest that NID1 could induce novel functional responses on NK cells. 
Analysis of SN obtained from NID1-stimulated NK cells is currently underway and might reveal whether 
NK cell secretome could be modified by NID1. 
4.9. NID2 COULD REPRESENT ANOTHER SOLUBLE MOLECULE 
RECOGNISED BY NKp44 
Since Nidogen family comprises NID1 and NID2 proteins that share similar functions and structure, we 
were interested in investigating whether NKp44 could also recognise NID2. To this end, the reactivity 
of different Fc molecules in the presence of NID2 was analysed by ELISA, utilising plates coated with 
rNID1, rNID2, or rHMGB1 as a negative control. Fig. 26A shows that NKp44Fc could interact with rNID2 
more weakly than with rNID1. Given these results, we evaluated the effect of rNID2 pre-treatment on 
Bw-NKp44 cells: our preliminary results indicate that pre-treatment with two different rNID2 
concentrations had no effect on Bw-NKp30 cells, while on Bw-NKp44 cells it produced a weaker 
inhibition as compared to that obtained with the same rNID1 concentration (Fig. 26B). 
 
Figure 26. Recognition and functional effect of rNID2  
(A) ELISA plates were coated with rNID1, rNID2 or HMGB1 followed by incubation with 20 g/ml of 
different Fc molecules and HRP-conjugated anti-human IgG mAb. Graph represents absorbance at 405 nm 
after normalization to background (nonspecific binding of the secondary reagent). Data are medians of 
triplicates ± interquartile range and are the pooled results of three independent experiments; 
****p<0.0001 by two-tailed Mann-Whitney test. (B) Bw-NKp44 and Bw-NKp30 cells were left untreated 
or pre-treated with rNID1 or rNID2 (20 or 7.5 g/ml) and subsequently incubated on anti-NKp44 or anti-
NKp30 mAb-coated plates, respectively. IL-2 release in the SN was evaluated by ELISA. The background 
(from GAM-stimulated cells) was subtracted for each value. Data are medians of duplicates ± interquartile 
range and are the pooled results of two independent experiments. *p=0.0286, ns=0.0571 (NID1 7.5 
g/ml), 0.3429 (NID2 20 g/ml) or 0.4857 (NID2 7.5 g/ml) by two-tailed Mann-Whitney test. 
Further experiments will be conducted in order to elucidate the functional role of NID2-NKp44 
interaction more precisely.  
4.10 NKp44 DOES NOT RECOGNISE LAMININ 
The initial analysis of spot 26 excised from 2-DE preparative gel also revealed the presence of laminin-
1 as a second glycosylated protein identified by mass spectrometry with a high number of peptides. 




In order to evaluate whether NKp44 could interact also with this protein, dot blot experiments were 
performed adsorbing human purified laminin and HEK293T-SN on a nitrocellulose membrane and 
probing it with different Fc molecules: Fig. 27A shows that no recognition of laminin by NKp44Fc under 
native conditions was observed. In order to rule out that NKp44Fc could recognize human laminin 
under denaturing conditions, we performed Western blot experiments, demonstrating that NKp44Fc 
was unable to recognize denatured laminin as well; moreover, the staining with an anti-laminin-1 
mAb revealed in HEK293T-SN the presence of two bands with a different MW as compared to the band 
recognised by NKp44Fc (Fig. 27B). These experiments showed that NKp44 did not recognise laminin 
neither under denaturing conditions nor in its native conformation. 
 
Figure 27. Analysis of NKp44Fc reactivity with purified human laminin  
(A) Concentrated HEK293T-SN and purified human laminin were spotted on a nitrocellulose membrane 
and subsequently stained with anti-laminin -1 mAb, NKp44, or NKp30Fc followed by the appropriate 
secondary HRP-conjugated secondary mAb. One representative experiment of two is shown. (B) 
Concentrated HEK293T-SN and purified human laminin were analysed on a 7.5% polyacrylamide gel and 
subsequently immunoblotted with anti-laminin -1, NKp44Fc, or NKp30Fc followed by HRP-conjugated 
anti-mouse IgG or anti-human IgG mAbs. One representative experiment of two is shown. 
5. DISCUSSION 
Our data describe the identification and characterisation of Nidogen-1 (NID1 or Entactin), a component 
of the Extracellular Matrix (ECM) (176), as a novel NKp44 soluble ligand. A preliminary analysis of cell 
culture supernatant derived by HEK293T cell line, expressing NKp44 ligand(s), suggested the presence 
of soluble glycoproteins recognised by NKp44. The subsequent analysis of HEK293T-SN by 2-DE 
coupled with high resolution mass spectrometry led to the identification of NID1 as a candidate ligand 
for NKp44 NK cell receptor. NID1-NKp44 interaction was next confirmed by immunoprecipitation 
experiments performed on HEK293T-SN, and by Western blot and ELISA experiments conducted on 
rNID1. Importantly, these results suggested that NID1-NKp44 recognition could occur under native 
conditions. However, NKp44 was shown to interact also with denatured NID1, suggesting that it could 
bind a linear epitope.  




Functional experiments, performed on the Bw-NKp44 cellular model showed that NID1 in soluble form 
(sNID1) could inhibit NKp44-induced IL-2 release: this inhibition was obtained using both rNID1 and 
sNID1 derived from cell transfectants. More importantly, we demonstrated that sNID1 derived from 
cell transfectants could inhibit NKp44-induced IFN- release in human polyclonal NK cells. We also 
evaluated the effect of sNID1 on NK cell cytotoxicity and observed a slight reduction of NK cell-
mediated killing of P815 target cells in the presence of sNID1. sNID1-mediated inhibition of NK cell 
function was specific for NKp44 receptor, nevertheless we observed that high rNID1 concentrations 
slightly inhibited IL-2 release also in Bw-NKp30 cells. However, the inhibitory effect on NKp30 was not 
evident when both Bw-NKp30 and NK cells were treated with sNID1 derived from cell transfectants; 
indeed, the interaction between NKp30 and rNID1 was not observed neither by ELISA nor by Western 
blot. Notably, NID1-mediated inhibition of cytokine release through the interaction with NKp44 
receptor was also demonstrated in both Bw-NKp44 and NK cells stimulated with PDGF-DD. These 
results indicate that NID1 could inhibit cytokine release not only induced by mAb-mediated NKp44 
crosslinking but also stimulated by a specific NKp44 ligand, i.e. PDGF-DD (127). Altogether our data 
suggest that NID1 might be able to act as a decoy ligand, similarly to other NK cell receptor soluble 
ligands. High levels of soluble ligands for DNAM-1, NKG2D, and NKp30 receptors were associated to 
advanced stage of disease or poor prognosis in different types of cancer, such as melanoma, ovarian 
cancer, and CLL (89,131,135,136,144,151–153). Shedding of membrane-bound ligands, such as B7-H6 
and MICA/B, is mediated by the activity of proteases that are usually highly expressed in the tumour 
site (134,145–148). In the last years, several studies described NID1 as a potential marker of tumour 
progression and prognosis: for example, elevated levels of sNID1 in the serum of ovarian cancer 
patients and in the secretome of lung metastasis, derived from breast cancer and melanoma, have 
been reported (194–200); moreover, a pro-tumoural and pro-metastatic role for NID1 has been 
demonstrated. Indeed, studies conducted on ovarian carcinomas showed that NID1 plays an important 
role in inducing EMT processes and chemoresistance in tumour cells, while NID1 involvement in 
tumour invasiveness and metastasis has been shown in the case of endometrial cancer and lung cancer 
(193,201,203). Therefore, sNID1-NKp44 interaction might represent a novel escape mechanism 
exploited by tumours to avoid NK cell-mediated killing. On the other hand, other studies demonstrated 
that NID1 loss may favour tumour invasiveness and spreading of tumour metastasis, due to the loss of 
BM integrity (192,202). Indeed, in the tumour microenvironment, NID1 could be exposed to the action 
of extracellular proteases, such as MMP-19, Cat-S, and ADAMTS1 (190,192,193): in particular, a specific 
fragment of NID1, derived from CatS-mediated degradation, found in the serum of NSCLC patients, 
was suggested to reflect the loss of BM integrity, typically associated to tumour progression (191). 
Western blot experiments performed with solubilised BM preparations indicated that NID1 could be 
present as a cleaved protein and that NKp44 could recognise a band of about 70 kDa, approximately 




corresponding to the one detected with a NID1-specific mAb. This observation, together with the 
ability of NKp44Fc to recognise denatured NID1, might indicate that NKp44 interacts also with cleaved 
forms of NID1. Furthermore, NID1-NKp44 recognition and its functional outcome might be influenced 
not only by protease-mediated NID1 degradation but also by NID1 interaction with different ECM 
proteins, such as laminin, collagen type IV, and perlecan (176,186,187). Indeed, regarding NID1-NKp44 
interaction, a possible functional role of perlecan should be considered. Since HSPGs, such as perlecan, 
have been described as co-ligands for NCRs (105,118), NKp44 recognition of NID1 in the presence of 
perlecan may induce a stronger modulation of NK cell-mediated cytokine release and cytotoxicity. 
Further studies should be undertaken to uncover the role of proteases and BM components in NID1-
NKp44 interaction; additional insights in this direction and the identification of NID1 epitope 
recognised by NKp44 might provide new perspectives for NK cell-based cancer immunotherapy. 
The presence of NID1 in exosomes derived from samples of healthy and cancer patients has been 
documented (194–199). Our preliminary data indicate that NID1 might be exposed at the surface of 
exosomes and MVs derived from HEK293T cells; therefore, it is possible that NK cell functions could 
also be influenced by NID1+ extracellular vesicles. Different studies conducted on tumour-related 
exosomes revealed that they might carry immunosuppressive molecules (i.e. immune checkpoint 
receptor ligands, noncoding RNAs, and inhibitory cytokines) involved in the dampening of the immune 
response (172). Further studies are required to evaluate how NID1+ exosomes might influence NK cell 
functions in the context of tumour microenvironment.  
Importantly, we demonstrated that NID1 is not only a soluble protein but could also be detected at 
the cell surface. Several studies suggested that NID1 can be found associated to cell membrane 
through the interaction with V3 and 31 integrins (178,181). Our data clearly demonstrated NID1 
expression at the cell surface of different tumour cell lines by flow cytometry; this finding was also 
supported by single cell imaging analysis of HEK293T cells. In addition, these results were confirmed 
by flow cytometry analysis of K562- and Bw-NID1 transfectants, as well as by silencing experiments 
conducted on HEK293T cell line: staining with anti-NID1 mAb correlated with NID1 expression in both 
NID1 transfectants and NID1-silenced cells. Notably, also NKp44Fc staining was increased or reduced 
according to NID1 expression, indicating that NKp44 could recognise not only sNID1, but also mNID1. 
Functional experiments, performed in order to study the role of mNID1, revealed that neither plastic-
bound NID1 nor NID1 cell transfectants could modulate the basal cytokine release in Bw-NKp44 and 
NK cells, whereas mNID1 could induce a slight increase of NK cell-mediated cytotoxicity. Interestingly, 
mass spectrometry analysis of NK cells stimulated with anti-NKp44 mAb or rNID1, revealed that plastic-
bound NID1 induced changes in NK cell proteome, influencing pathways involved in NK cell 
immunologic functions, metabolism, proliferation, and development. GO analysis of modulated 
proteins showed that both rNID1 and anti-NKp44 mAb stimuli resulted in similar functional effects. 




NID1 and NKp44 stimuli shared 15 proteins significantly modulated as compared to control samples: 
among them, 4 and 3 proteins were similarly up- and down-regulated, respectively, while 8 proteins 
were differentially modulated in rNID1- and NKp44-stimulated NK cells. One of the most significantly 
up-regulated proteins in both rNID1- and NKp44-stimulated NK cells was MYSM1. Interestingly, 
MYSM1 is a histone H2A deubiquitinase involved in mouse NK cell development (213), and mutations 
of MYSM1 in humans have been associated to low NK and B cell counts, as well as to mild 
thrombocytopenia (214). Studies on human NK cell development demonstrated that immature NK cells 
at different maturation stages express NKp44 receptor (215). Therefore, the investigation of the 
functional role of NID1-NKp44 interaction on NK cell maturation and the effect of such interaction on 
MYSM1 expression, in both immature and cytokine-activated mature NK cells could be very relevant. 
Studies on mucosal ILC3 demonstrated that NKp44 engagement induces TNF and IL-22 production 
(216), as well as a wide modification of ILC3 transcriptome (85). Similarly, proteomic data obtained 
from NID1-stimulated NK cells suggest that NID1 could be involved in modulating novel NKp44-
mediated NK cell functions by inducing a broad alteration of NK cell proteomic profile. Since NID1 is 
highly expressed in different tissues, such as mucosae and decidua (182), where NKp44-expressing 
cells can be found (12,13), NID1 effect on ILC3 and other NKp44+ cells should be explored. Within 
decidua tissue dNK cells play an important role in maintaining an immunosuppressive 
microenvironment (18–20): the role of sNID1-dNK cell interaction should be studied, keeping in mind 
that the outcome of this interaction could also be influenced by the expression of different NKp44 
isoforms (76,77). 
NID1 is a member of Nidogen family that comprises also NID2 protein (176): NID1 and NID2 share 
similar functions and structure. Our preliminary data suggest that rNID2 could interact with NKp44 and 
inhibit NKp44-mediated cytokine release, even if at a lesser extent than NID1. However, more data 
need to be collected regarding the relevance of NID2 in the context of NKp44 recognition.  
In conclusion, NID1 characterization as an extracellular ligand for NKp44 provides new insights in the 
complexity of NK cell biology. Further investigations on the potential functional effects of NID1 
degradation by ECM proteases and interaction with other ECM components are necessary to fully 
understand NKp44-mediated mechanisms regulating NK cell functions. Our proteomic analysis also 
suggests that NKp44 could be involved in regulating different biological processes, thus indicating 
novel NK cell functions. Collectively, our data and future studies might lead to new approaches for NK 
cell-based immunotherapy. 
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